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Cancer is a genomic disease driven by interplay between genetic and epigenetic 
factors. While genetic mutations are irreversible events, epigenetic regulation is dynamic 
and reversible, and small molecule blockade of the epigenetic machinery has shown 
clinical benefit in hematological malignancies. However, the promise of epigenetic 
therapy has yet to be realized in solid tumors due do limited efficacy and elevated risk of 
toxicity. Development of potent and specific inhibitors targeting the histone methylation 
machinery shows promise in tailoring epigenetic therapy for a specific malignancy and 
decreasing the risk of off-target effects.  
One such target of interest is the histone lysine-specific demethylase 1 (LSD1). 
Several solid malignancies show upregulation of LSD1 associated with an aggressive 
clinical course. Validation of LSD1 as a target has been limited by poorly potent and non-
specific tool compounds, hindering evaluation in in vivo models of disease. This work 
describes the discovery of a novel potent, specific, and reversible series of LSD1 
inhibitors. The identified lead compound, HCI2509, is a noncompetitive inhibitor with 
nanomolar affinity for LSD1. HCI2509 impaired cell viability across several human 
cancer cell lines, with both Ewing sarcoma and endometrial cancers showing particularly 
potent responses. 
Ewing sarcoma is a rare and aggressive pediatric malignancy characterized by by 
the chromosomal translocation-derived EWS/ETS fusion proteins. EWS/ETS fusions act 
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as oncogenic transcription factors and facilitate cellular reprogramming through the 
activation of oncogenes and repression of tumor suppressors. Treatment with HCI2509 
reverses both EWS/ETS-mediated transcriptional activation and transcriptional 
repression, and leads to apoptotic cell death in Ewing sarcoma cells. Notably, HCI2509 
shows single-agent efficacy in xenograft models of Ewing sarcoma and represents a new 
therapeutic strategy for this devastating disease. 
HCI2509 also shows single-agent efficacy in a xenograft model of Type II 
endometrial carcinoma. Cases of Type II endometrial carcinoma comprise 11% of the 
incidence and 48% of the deaths due to endometrial cancer annually, such that new 
therapies are needed for this aggressive subtype. Reversible LSD1 inhibition was 
associated with tumor regression in an orthotopic model of this disease. These results 
demonstrate the promise of targeting the histone methylation machinery, specifically 
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“Nothing in life is to be feared, it is only to be understood. Now is the time to  
understand more, so that we may fear less.” 
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 While genetic information encoded in DNA contains the program for every cell, 
cell- and tissue-specific programming required for normal physiological function are 
regulated by a dynamic array of epigenetic and transcriptional machinery (1). This 
epigenomic level of regulation allows interaction between one's environment and one’s 
genes and can result in heritable patterns of gene expression in the absence of genetic 
mutation. Cancer is a disease of the whole genome, characterized by both genetic
aberrations and epigenomic misregulation driving the malignant phenotypes 
comprehensively described by Hanahan and Weinberg (2). Worldwide, the incidence of 
cancer is projected to double from 12.7 million new cases in 2008 to 21.4 million new 
cases, and 13.5 million deaths, by 2030 (3). Given that genomes and environments are 
singular for each patient, each individual malignancy is unique, such that universally 
efficacious treatment options are nonexistent. However, where genetic mutations are 
irreversible, the dynamic nature of the epigenetic machinery is susceptible to 
pharmacological intervention. Epigenetic enzymes which fuel oncogenic misregulation 
are emerging therapeutic targets.  
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 The histone demethylase lysine specific demethylase 1 (LSD1) is one such target 
and is either upregulated in or critically important to the development and progression of 
various cancers, including neuroblastoma (4), acute myeloid leukemia (5), and prostate 
cancer (6). However, having only been discovered in 2004, the complicated biological 
mechanisms which regulate LSD1 function in healthy and diseased states are not yet fully 
elucidated. Moreover, the available tool compounds suffer from both poor potency and 
specificity, complicating interpretation of reported results. Hence, we pursued a drug 
discovery program to identify potent, specific and reversible LSD1 inhibitors to use as 
tool compounds to preclinically screen the viability of LSD1 inhibition as a therapeutic 
strategy for solid tumors. The discovery of such a series will further enable detailed 
investigation of the biological role of LSD1 in various cancers, and diffentiate 
mechanisms that are common between malignancies and those that are more disease-
specific. While this work focuses primarily on Ewing sarcoma and endometrial cancer, 
the compound series identified may provide therapeutic benefit in a diverse array of 
cancers for which LSD1 overexpression has been reported or LSD1 biology implicated.  
 
1.2 Summary of this Dissertation 
 This chapter will provide an overview of the rapidly evolving field of cancer 
epigenetics, describing both the clinical challenges encountered to date by FDA-approved 
epigenetic therapies and the ways in which second generation epigenetic targeted 
therapies address these, focusing specifically on the challenges and promises of targeting 
LSD1. Additionally, this chapter will introduce the rationale for the studies described 
herein and identify the objectives met in Chapters 2-4. Chapter 2 describes the initial 
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discovery, hit-to-lead optimization, and biochemical characterization of the N'-(1-
phenylethylidene)-benzohydrazide series of LSD1 inhibitors that are the subject of the 
remainder of the dissertation.  
 Chapters 3 and 4 describe validation of the activity of LSD1 inhibition in two 
solid tumors of interest, Ewing sarcoma and Type II endometrial carcinoma. Chapter 3 
investigates the unique activity of the lead compound, HCI2509, in Ewing sarcoma, 
focusing both on characterizing the effects of HCI2509 on the molecular drivers of Ewing 
sarcoma in vitro and validating single-agent efficacy in xenograft models in vivo. Ewing 
sarcoma is driven solely by the chromosomal translocation leading to expression of an 
EWS/ETS fusion oncoprotein and transcription factor, lacking additional genomic 
aberrations (7). Subsequent transcriptional reprogramming relies heavily on 
misregulation of the transcriptional and epigenetic machinery, presenting an ideal proof-
of-concept system for in vivo studies. Chapter 4 moves beyond this to Type II 
endometrial cancer, which primarily occurs in adulthood, is clinically aggressive, and is 
driven by a more diverse and complex set of genetic, epigenetic, and environmental 
factors. In this chapter, studies describe both the in vitro anticancer effects of HCI2509 in 
multiple cell lines and the in vivo antitumor efficacy of HCI2509 in an orthotopic model 
of Type II endometrial cancer. Chapter 5 provides conclusions while also outlining future 
work suggested by the results described herein. Additionally, three appendices include 
data which were critical to the completion of these studies, but not published, including 






1.3.1 Epigenetics and Cancer Pathogenesis 
 Epigenetics broadly refers to four layers of dynamic regulation within the nucleus: 
DNA methylation, histone posttranslational modifications, nucleosome positioning, and 
the expression of various noncoding RNAs. Mounting evidence implicates all four levels 
in the development and maintenance of oncogenic gene expression programs 
characteristic of cancer. However, the roles that nucleosome positioning and noncoding 
RNAs play in cancer are outside the scope of this work. 
  
1.3.1.1 DNA Methylation 
 DNA methylation in mammals occurs only on cytosine bases that are 5' linked to 
guanosine (CpG) (8). Methylation is catalyzed by DNA methyltransferases (DNMT) 
DNMT1, DNMT3a, and DNMT3b. DNMT1 acts only on hemimethylated DNA and is 
responsible for the maintenance of DNA methylation patterns during replication, while 
both DNMT3a and 3b are capable of de novo DNA methylation (9,10). Cytosine is 
largely underrepresented in the genome with the exception of short regions (0.5-4 kb) 
called CpG islands, which are GC enriched (8,11). CpG islands are located at the 
proximal promoter region of roughly 50% of genes in the human genome (11). DNA 
methylation at the promoter functions to silence the downstream gene. As a cell 
progresses through normal development, increased promoter methylation at particular 
loci silences expression of genes which are lineage-inappropriate, reinforcing cellular 
differentiation (10). In cancer, global genomic demethylation is observed, with increased 
methylation occurring at the promoter regions of tumor suppressor genes (12,13). Many 
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of the silenced tumor suppressors are known to be frequently mutated, like MGMT, 
CDKN2A, MLH1, and BRCA1, suggesting both genetic and epigenetic routes can lead to 
the same oncogenic phenotype (14-18). 
 In addition to the promoter hypermethylation observed across human neoplasms, 
DNA methylation can itself promote C to T mutations through spontaneous hydrolytic 
deamination (19). This effect is not insignificant, up to 50% of the inactivating mutations 
of the tumor suppressor TP53 occur at methylated cytosines (20). Additionally, cancer 
cells display genomic hypomethylation outside of the proximal promoter regions (21,22). 
This global loss of methylation is thought to contribute to genomic instability and 
structural alterations of chromosomes (23). Overall, changes in DNA methylation were 
the first characterized epigenetic phenomena observed in cancer, and inspired the 
development of pharmacological agents targeting the DNMTs, the first FDA-approved 
epigenetic therapies for cancer, discussed in section 1.3.2. 
 
1.3.1.2 Histone Modifications 
 In order to fit the whole genome into the nucleus, eukaryotic cells utilize a 
packing scheme in which 147 bp of DNA is wrapped around an octameric complex 
containing two each of histone 2a (H2a), histone 2b (H2b), histone 3 (H3), and histone 4 
(H4) (1). This DNA-histone complex comprises the nucleosome, which is further 
compacted into chromatin. Tightly compacted chromatin is termed heterochromatin, and 
genes located here are repressed or silenced, whereas euchromatin has an open 
conformation allowing the transcriptional machinery access to promote active gene 
expression (1). Conserved residues on histones, often found on the unstructured and 
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lysine-rich N-terminus, are subject to a variety of posttranslational modifications 
including methylation, acetylation, phosphorylation, SUMOylation, and ubiquitinylation, 
such that histone modification is more diverse and dynamic than DNA methylation (24). 
Particular modifications act combinatorially such that various patterns of modifications 
interact with DNA- and chromatin-binding proteins to define chromatin status and recruit 
transcriptional machinery. Using the N-terminal tail of H3 as an example, 
heterochromatin is marked by increased H3K9 and H3K27 trimethylation as well as DNA 
methylation, whereas euchromatin is characterized by acetylation at H3K9 and H3K16 
(25). While acetylation of histone residues directly affects gene accessibility through 
increasing the strength of the DNA-histone electrostatic repulsion, histone methylation 
plays an important, but more complex, role in transcriptional regulation. Notably H3K9 
and H3K27 methyl marks are repressive, where methylation at H3K4 is permissive and 
commonly found associated with the proximal promoter of actively transcribed genes 
(24,25).  
 The suite of histone modifications are written, erased, and read by a diverse 
complement of biomolecules, including proteins and nucleic acids. Often complexes 
possessing opposing functions are found co-localized in the nucleus, facilitating context-
dependent dynamism (26-28). The existence of bivalent domains, containing both 
activating and repressive histone marks, further undrescores the importance of 
epigenomic dynamism (29,30). Using histone acetylation as an example, acetyl marks are 
written by histone acetyltranferases (HATs), including the p300/CBP, GNAT, and MYST 
subfamilies, and erased by histone deacetylases (HDACs) (31). Acetylated histone lysines 
are recognized by proteins which contain a structural motif termed a bromodomain. 
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Bromodomain-containing proteins include chromatin remodelers, HATs, histone 
methyltransferases, and transcriptional co-activators and often possess another histone 
reader domain, such as the methyllysine-specific PHD finger, to facilitate combinatorial 
recognition of the chromatin state (32).  
 Aberrant global histone acetylation patterns are broadly observed in cancer (32), 
and many studies have implicated HATs, HDACs, and bromodomains in malignant 
epigenetic misregulation. For example, HATs are present in multiple oncogenic fusion 
proteins (33), the most well known being MOZ-TIF2 in aggressive leukemia (34,35).  
Somatic mutations are also documented in HATs, such as those documented in p300/CBP, 
in various solid tumors and hematological malignancies (36,37). While somatic mutations 
are not observed as commonly in HDACs, levels of HDAC expression are often altered 
in cancer, with overexpression correlating with aberrant silencing of tumor suppressor 
genes and impaired apoptosis (38,39). With respect to histone readers, mutations in 
bromodomain-containing proteins have also been documented in acute lymphocytic 
leukemia (ALL), midline carcinoma, renal carcinoma, and breast cancer (31). 
  
1.3.2 Implications of Cancer Epigenetics for Therapy 
 These observations illustrate an emerging paradigm, whereby genetic mutations 
and epigenetic factors are two sides of the same coin. It should be noted that discoveries 
analagous to those described for HATs implicate mutations in DNMTs, the histone lysine 
methylation machinery, nucleosome remodelers, and noncoding RNAs in carcinogenesis. 
In fact, mutations in epigenetic regulators are now documented in almost all human 
malignancies (40-51). Alterations in the epigenetic regulatory machinery lead to genomic 
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instability, which further promotes mutations in other tumor suppressors and epigenetic 
proteins, further compounding epigenetic misregulation, and so on. However, unlike 
genetic drivers of cancer, epigenetic modifications are often reversible, presenting 
opportunities to pharmacologically disrupt and reverse malignant programming. 
Understanding the interplay and intersection between genetic and epigenetic factors is of 
critical importance to determine the most appropriate and efficacious way to 
therapeutically target genomic misregulation in cancer. Most importantly, better tools are 
needed to determine which epigenetic players represent oncogenic drivers in a given 
malignancy, such that small-molecule blockade disproportionately affects the cancer cell 
while leaving required epigenetic and genomic regulatory mechanisms intact in normal 
tissue. To date, DNMT inhibitors and HDAC inhibitors, are FDA-approved and their 
clinical use over the past decade has enhanced our knowledge about the promises and 
challenges of epigenetic therapy in the clinic (Table 1.1).  
 
1.3.2.1 FDA-Approved Epigenetic Therapies 
1.3.2.1.1 DNA Methyltransferase Inhibitors 
 The DNA demethylating agents, decitabine and 5-azacytidine, were first designed 
as cytotoxic chemotherapy in the 1960s (52,53), and their activity against DNMTs was 
only established 20 years later (54). 5-azacytidine gained FDA-approval in 2004 for the 
treatment of myelodysplastic syndrome (MDS), while decitabine was approved in 2006 
for MDS and acute myeloid leukemia (AML) (55-58). Their approval was dependent 
upon drastic reductions in dose from the maximally tolerated dose, such that dose de-
escalation improved both tolerability and shifted the mechanism of action from cytotoxic 
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activity to DNMT inhibition (59). At low doses, the nucleotide analogue is incorporated 
into DNA and acts as a suicide inhibitor for the DNMT, triggering its degradation (60-
63). Pharmacokinetic studies of the doses used clinically shows nanomolar plasma 
concentrations, and at these exposures minimal cell death is observed in vitro (64). 
However, even after 1 exposure, increased expression of immunomodulatory and pro-
apopotic genes, as well as whole-genome demethylation were observed and coincided 
with decreased clonogenicity and tumorgenicity (64). Importantly, findings of durable 
cellular reprogramming seem to also apply to tumor stem-like cells (64). This suggests 
epigenetic therapies may be able to target this population of cells, which is typically 
resistant to multiple other treatment modalities and drives the metastases and disease 
recurrence that often prove fatal. These laboratory results are consistent with clinical 
observations of patients treated with DNMTs. A large proportion of the patient population 
treated with 5-azacytidine for AML or MDS need months before a response becomes 
apparent, perhaps due to long-term exhaustion of stem-like cells (65). Additionally, ~48% 
of high-risk MDS patients who prolonged DNMTi treatment duration beyond their initial 
response improved the magnitude of response with subsequent therapies (65). The 
clinical use of DNMT inhibitors has greatly improved therapeutic options for patient with 
both MDS and AML. 
 
1.3.2.1.2 Histone Deacetylase Inhibitors 
 The second class of FDA-approved epigenetic therapies are the histone 
deacetylase inhibitors. Both vorinostat and romidepsin were approved for the treatment of 
cutaneous T-cell lymphoma (CTCL), with romidepsin also indicated for the treatment of 
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relapsed peripheral T-cell lymphoma (66-69). Multiple additional HDAC inhibitors are in 
development, but are outside the scope of this work and are reviewed comprehensively 
by Lane, et al. (70). Whereas HDAC inhibitors have shown striking responses in CTCL, 
their value remains largely unproven elsewhere in the clinic, likely due to analogous but 
less understood differences in dose-dependent mechanisms of action, the discussion of 
which is beyond the scope of this work. 
 
1.3.2.2 Clinical Challenges Facing Epigenetics 
 In the indications where epigenetic therapy is approved significant clinical 
benefits have been observed. However, while epigenetic mechanisms play a central role 
in cancer pathogenesis across malignancies, clinical benefit in the most common solid 
tumor remains largely unachieved. The difficulty in translating epigenetic insights to 
clinical benefit stems from our limited understanding of the basic science through to the 
design and execution of clinical trials.  
 In the laboratory, prior to the advent of next generation sequencing and ensuing 
flood of genomic data, epigenetics research was heavily biased towards events occurring 
at the transcription start site.  As these research programs were initiated the most obvious 
and observable phenomena was DNA methylation at silenced gene promoters and the 
downstream effects on transcription (51). However, cancer manifests at the level of the 
whole genome as is visible in the nuclei of cancer cells under a microscope.  In the new 
era of “-omics,” our understanding of the global epigenomic events leading to cancer is 
ceretainly growing, however, the detailed mechanisms by which these events occur and 
how exactly they drive tumorigenesis remain largely undetermined and unexplored.  
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 It is clear, however, that misregulation in the epigenome is far-reaching, 
representing a sort of software glitch that alters expression programs across hundreds of 
genes in diverse pathways and promotes tumorigenesis. Currently approved therapies 
clearly can rise to the challenge of targeting the cellular reprogramming.  The Peter A. 
Jones group has largely demonstrated durable reprogramming of cancer cells following 
long-term low exposure to DNMT inhibitors in cell culture (64). Additionally, the process 
of “reprogramming” induced pluripotent stem cells from differentiated adult cells is 
enhanced by DNMT and HDAC inhibitors (71-73). These results buttress the potential 
for epigenetic therapy to show sweeping effects in solid tumors. However, the sort of 
“knockdown-rescue” experiments that are required to prove causality and achieve 
mechanistic insight in this realm are largely beyond our technical prowess.  
 While comprehensive understanding of the mechanisms by which approved 
therapies act remains elusive, several empirical observations have informed the current 
paradigm for dose de-escalation in their clinical use. At high doses, both DNMT and 
HDAC inhibitors show cytotoxic effects, with the more potent on-target effects dominant 
at low doses (51). HDAC inhibitors are limited in that HDACs are fairly promiscuous 
enzymes and show diverse function (74,75). In fact, some HDACs are localized to the 
cytoplasm, such that an analysis of whether the antitumor efficacy seen with HDAC 
treatment are on- or off-target is largely confounded (74). These types of observations 
continue to muddy the water. 
 Early trials of epigenetic therapy in solid tumors followed traditional clinical trial 
design, using dose-escalation to identify the maximally tolerated dose (MTD). In Phase II 
efficacy testing, the MTD for both HDAC and DNMT inhibitors showed pronounced off-
12 
 
target cytotoxicity with little effect on the epigenetic pharmacodynamic endpoints. In 
order to evaluate the epigenetic activity of these classes of drugs, the doses needed to be 
reduced. This dose de-escalation was accompanied by the observation that cellular 
reprogramming was not apparent in the short-term, and required long-term 
pharmacodynamic monitoring (51). The high cytotoxic doses likely preclude the 
reprogramming required for true epigenetic therapy. Thus, clinical translation has been 
limited to date by suboptimal trial design which fails to account for the low-dose, long-
term efficacy expected with epigenetic drugs.  
 As such, innovative trial designs are required to build on the early data in 
hematological malignancies and establish a new paradigm for epigenetic treatment in 
solid tumors. This really is early days, as several fundamental parameters remain 
undefined. For example, the therapeutic window for reprogramming in malignant versus 
normal tissues, or the length of time and criteria used to assess response, are unknown 
and yet unstudied. Clinical evaluation of new epigenetic therapeutic strategies may 
benefit from trial design used in other fields, like translational immunotherapy, to assess 
these sorts of parameters (76). Encouragingly, these lessons have been learned and dose 
de-escalation is being tested clinically in solid tumors, including nonsmall cell lung 
carcinoma, colorectal, and breast cancers and with promising early results (77). 
 
1.3.2.3 Sensitizing Cancer to Other Treatments 
 Further optimization of DNMT and HDAC inhibitor dosing in solid tumors in the 
clinic will provide an opportunity to validate observations from the laboratory that 
cellular reprogramming induced by epigenetic targeted agents confers increased cellular 
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sensitivity to other modalities of treatment. This includes hormone therapy, 
chemotherapy, and immunotherapy either combined in parallel or implemented 
sequentially (51). Notably, Sharma, et al. (78) observed in vitro the existence of a drug-
tolerant population of cells in multiple human tumor cell lines. The drug-tolerant 
phenotype was transient and reversible, and mediated by both IGF-1 receptor signaling as 
well as chromatin changes, suggesting a role for dynamic epigenetic regulation in the 
development of drug resistance (78). Inhibition of IGF-1 receptor signaling, HDACs, and 
the histone lysine demethylase JARID1A ablated this phenotype, suggesting a potential 
role for epigenetic therapies to augment sensitivity to other systemic anticancer therapies 
(78). 
 
1.3.3 Emerging Epigenetic Targets 
 While DNMT and HDAC inhibitors provided proof-of-concept for epigenetic 
therapies in the clinic, insights from the last decade of cancer epigenetics research has 
uncovered mutations or aberrations in countless other classes of epigenetic regulators 
including histone mark readers, histone lysine methylation regulators, nucleosome 
remodelers, and the noncoding RNA machinery. This has resulted in a wave of target 
validation and drug discovery efforts across academia and industry. Several of these 
research tracks are now bearing fruit, with several novel classes of epigenetic targeted 
agents in Phase I and Phase II studies. For each program described herein, the Phase I 
studies have focused on or are studying a particular malignancy in which the target is an 
established driver of the disease, either through direct mutation or as a required player in 
epigenomic misregulation. This underscores the importance of picking the right patient 
14 
 
population with clear pharmacodynamic criteria for proof-of-concept studies.  
 Having optimized dosing and pharmacokinetic/pharmacodynamic relationships in 
these simpler populations, clinical research can move forward with the process of 
evaluating these agents in diverse patient populations with more complex disease states. 
This progress will lean heavily on continued insights from both basic and translational 
studies validating potential biomarkers to define the patient populations most likely to 
respond to different classes of epigenetic agents. The ultimate goal is to enable 
personalized epigenetic treatment for each individual malignancy. To date, the most 
advanced clinical programs are those targeting histone acetylation readers, or 
bromodomain inhibitors, and those targeting the histone lysine methylation machinery. 
 
1.3.3.1 Targeting Bromodomains 
 Protein-protein interactions are notoriously difficult to target with small 
molecules, however, a class of inhibitors, exemplified by the molecules JQ-1 and iBET, 
have been shown to disrupt the interaction of the BET family (BRD2, BRD3, BRD4, and 
BRDt) of bromodomain proteins with acetylated histone lysine residues. Bromodomain 
inhibitors represent the first epigenetic agents to target histone posttranslational readers.  
The bromodomain of BET proteins is highly conserved, plays a critical role in cell cycle 
progression and transcriptional elongation, and is involved in translocations which drive 
the fatal NUT-midline carcinoma. In vitro and in vivo studies of the BET inhibitors 
consistently showed both downregulation of MYC transcript and disruption of the MYC 
transcriptional program across a wide variety of hematological and solid malignancies, as 
well as disruption of superenhancer motifs that reinforce MYC and BLC2 expression (79-
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88). At the time of writing three BET inhibitors programs had initiated clinical trials, with 
GSK525672 in two Phase I trials for NUT midline carcinoma and relapse or refractory 
hematological malignancies (89), TEN-010 for advanced solid malignancies or NUT 
midline carcinoma (90), and CPI-0610 in previously treated and aggressive lymphomas 
(91).  
 
1.3.3.3 Targeting Histone Lysine Methylation 
 While histones can be methylated at lysine, arginine, and histidine side chains, 
lysine methylation is the best characterized and disproportionately represents the 
therapeutic development by targeting histone methylation, so it will be the focus of 
discussion. Unlike acetylation and phosphorylation, lysine methylation does not alter the 
charge of the residue. Of the posttranslational modifications, methylation shows the 
slowest turnover (92) and was originally thought to be irreversible, until the discovery of 
the first histone lysine demethylase in 2004 (93). Lysine residues can be either mono- 
(me1) (94), di- (me2) (95), or tri-methylated (me3) (96). Methylation at histone H3 lysine 
4 (H3K4), lysine 9 (H3K9), lysine 27 (H3K27), lysine 36 (H3K36), lysine 79 (H3K79), 
and histone H4 lysine20 (H4K20) are the most studied, and a plethora of methyl mark 
writers, readers, and erasers have been identified which display diverse substrate 
specificities and allow for nuanced control of histone methylation status (Figure 1.1). 
Broadly speaking, methylation at H3K4, H3K36, and H3K79 typically correlates with 
euchromatin, while that at H3K9, H3K27, and H4K20 corresponds to repressive 
heterochromatin (31).  Even more specifically, some methylation states may require 
stability through mitosis, such as established silencing within heterochromatin, while 
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others depend upon dynamism, so as to facilitate cell differentiation in response to 
external stimuli. Additionally, different modifications on the same residue may denote 
specific chromatin states. For example, H3K9me1 is typically associated with active 
chromatin, while H3K9me3 is associated with repressed genes (31). Moreover, these 
marks may distribute to different regions spatially, for example, H3K4me1 is found 
within enhancer regions of the genome, while H3K4me2/3 is enriched at the transcription 
start sites of actively-transcribed genes (31). This model of complexity between different 
marks and within methyl marks on the same lysine is supported by the observation that 
methyl marks at different lysine residues display different turnover rates (97). 
 The dynamics of histone methylation are regulated by histone lysine 
methyltransferases (KMTs) and histone lysine demethylases (KDMs). KMTs catalyze the 
addition of methyl marks to lysine from S-adenosylmethionine (94) and fall into one of 
two families, either the SET-domain containing proteins (98) or DOT1L-like proteins 
(99). KDMs likewise fall into two classes, either the amine oxidases (94) or jumonji C 
(JmjC)-domain containing, iron-dependent dioxygenases (100,101). In addition to the 
complexity by which histone methylation regulates chromatin, many KMTs and KDMs 
also act upon nonhistone substrates, challenging the interpretation of the biological role 
for these enzymes in the cell. 
 Like DNA methylation and histone acetylation, histone lysine methylation has 
been widely implicated in the development of various malignancies both through 
alterations in levels of expression as well as through mutation of KMTs and KDMs. The 
complete details of this are beyond the scope of this work, but are reviewed 
comprehensively by Albert and Helin (102) and Chi et al. (103). Broadly speaking, 
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various malignancies show aberrations in the global levels of histone lysine methyl 
marks, most commonly hypomethylation, that are associated with poorer survival, worse 
clinical outcomes, or higher disease recurrence (Table 1.2) (104). While causality remains 
unestablished, these observations may lead to the development of future biomarkers. At 
the interface between genetics and epigenetics, genomic studies have also identified 
several somatic mutations in the histone lysine methylation machinery or chromosomal 
translocations which involve KMTs or KDMs, further implicating misregulation of 
histone methylation in oncogenesis (102-104).  
 To date, two KMTs have proven to be tractable targets for the development of 
pharmacological inhibitors.  The first is DOT1L, a KMT with specificity for H3K79 (99). 
Roughly 5-10% of acute leukemias, particularly infant and relapsed leukemias, present 
with a chromosomal translocation involving the KMT MLL at 11q23 (105). Loss of the 
C-terminus of MLL in rearrangements replaces the SET KMT domain with sequences 
derived from AF4, AF9, AF10, and ENL (105). These domains interact directly with 
DOT1L to maintain the MLL-r fusion-driven oncogenic transcriptional activity, such that 
DOT1L is necessary for transcription of key target genes driving leukemogenesis (105). 
Epizyme recently concluded the dose-escalation portion of their Phase I study of the 
DOT1L inhibitor, EPZ-5676, and began enrolling for the expansion phase of the trial in 
December 2013 (106). This was the first histone methyltransferase inhibitor to enter the 
clinic. 
 The second KMT with drug development programs entering early clinical studies 
is enhancer of zeste homolog 2 (EZH2). EZH2 is a KMT with substrate specificity for 
H3K27 and is the catalytic subunit of the polycomb repressive complex 2 (PRC2), 
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promoting gene silencing.  EZH2 is a prime example of target complexity when 
considering histone methylation. EZH2 is observed in numerous cancers including breast 
(107), prostate (108), lung (109), skin (109), and colon cancer (109), as well as 
lymphomas (110). B-cell lymphomas have also been shown to contain somatic activating 
point mutations in EZH2, supporting its role as an oncogene (110). Further buttressing 
this model, the histone demethylase with substrate specificity for H3K27, UTX, contains 
inactivating point mutations in a variety of cancers (111). However, loss-of-function 
EZH2 mutations in MDS have been reported (112), highlighting the context-dependence 
of a single epigenetic target in a given disease. The second KMT inhibitor to enter the 
clinic was Epizyme's EPZ-6438, with the dose escalation study still active for patients 
with advanced solid tumors and relapsed or refractory B-cell lymphoma (113). 
GlaxoSmithKline has also initiated clinical trials with their EZH2 inhibitor, 
GSK2816126, in patients with relapsed or refractory diffuse large B cell and transformed 
follicular lymphoma (114). 
 In addition to KMTs, KDMs are attractive therapeutic targets in various cancers. 
Beyond genetic aberrations, expression levels of various KDMs are observed across 
many human malignancies (Table 1.3) (115). The first KDM inhibitor to reach the clinic 
is GSK2879552, an irreversible inhibitor of lysine specific demethylase 1 
(LSD1/KDM1A) with Phase I studies initiated in early 2014 for patients with relapsed or 






1.3.4 Lysine Specific Demethylase 1 
 Somatic mutations in KDM1A are not observed in cancer, but LSD1 
overexpression has been documented in a number of both hematological and solid 
malignancies and is typically associated with de-differentiation, aggressive biology, and 
poorer outcomes. Increased levels of LSD1 are a biomarker for aggressive tumor biology 
and poor prognosis in breast (117) and prostate cancers (118-121). In prostate cancer, the 
overexpression of LSD1 promotes ligand-independent androgen-receptor-dependent 
transcription (119,120). LSD1 expression is inversely correlated with differentiation in 
neuroblastoma, suggesting a role in repressing differentiation (122). Interaction of the 
transcription factor TAL1 with LSD1 drives hematopoietic differentiation programs, with 
aberrant function of this axis observed in ~60% of T-cell acute lymphoblastic leukemia 
(123,124). In acute myeloid leukemia, LSD1 blocks differentiation and perpetuates the 
cancer stem-cell compartment (125,126). Upregulation of LSD1 has also been observed 
in bladder (127,128), lung (127), colorectal tumors (127), high grade sarcomas (129,130), 
and hepatocellular carcinoma (131,132). 
 
1.3.4.1 Discovery, Structure, and Function 
 LSD1 is the main histone demethylase in the cell and comprises an 852 amino-
acid flavin adenine dinucleotide (FAD)-dependent amine oxidase, depicted in Figure 1.2 
(94). The discovery of this enzyme, conserved from yeast through humans, was the first 
concrete evidence for dynamic regulation of histone methylation. The first 171 N-
terminal residues are unstructured, but appear to act as a tether for interactions with other 
proteins in chromatin-remodeling complexes (133,134). The majority of conserved 
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residues reside in close proximity to the amine oxidase domain (AOD) and appear to 
facilitate ligand packing and binding (133,134). The AOD is conserved and homologous 
to monoamine oxidases (MAO) A and B, as well as polyamine oxidase (PAO) (133,134). 
Like the MAOs, LSD1 binds FAD in a conserved Rossman fold, however, unlike the 
MAOs, LSD1 bind FAD noncovalently (133,134). The FAD cofactor binding pocket is a 
narrow cavity through the center of the enzyme and within this pocket FAD interacts with 
LSD1 through salt bridges with Arg310 and Arg316. The isoalloxazine ring system is 
positioned for catalytic activity at the base of the substrate binding pocket near Lys661 
(133). The FAD is reduced during the formation of the imine intermediate. Hydrolysis of 
the imine leaves the demethylated lysine and releases a molecule of formaldehyde, while 
the FADH- is oxidized to FAD by oxygen, releasing a molecule of H2O2 (Figure 1.3) 
(135). Lys661 is critical for enzymatic activity by channeling molecular oxygen for 
FADH- oxidation and recharging the redox potential at the catalytic site (136). 
 Other domains include a Swi3p, Rsc8p and Moira (SWIRM) domain and a tower 
domain. In most proteins, SWIRM domains interact directly with DNA, though this is not 
the case for LSD1. The tower domain, required for enzymatic activity (134), is a coiled-
coil sequence inserted within the AOD which prominently protrudes as a docking site for 
additional protein-protein interactions, such as that with Co-REST, a common binding 
partner for LSD1. Co-REST contains two SANT domains, which confer DNA-binding in 
place of LSD1's odd SWIRM domain, and are required for functional demethylation of 
residues in the native nucleosome (133).  
 LSD1 demethylates both mono- and di-methyl marks on H3K4 and H3K9 
(94,118). Methylation of H3K4 is associated with gene activation, while H3K9 
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methylation generally denotes gene repression. Due to the imine intermediate formed 
during demethylation, removal of the trimethyl mark is chemically inaccessible to LSD1 
(134). The substrate N-terminal tail of H3 packs tightly into the asymmetric funnel-
shaped binding pocket of LSD1. The amine terminus of H3Ala1 is bound in a highly 
electronegative pocket showing hydrogen bonding and electrostatic interactions with 
Asp555 of LSD1 (137). Lys4 is oriented toward the isoalloxazine ring system to facilitate 
oxidative attack on the N-CH3 group by flavin (137,138). Residues 1-5 of histone H3 
adopt a helical turn, 6-9 are sharply bent, and residue 10-16 are more extended and 
partially solvent exposed along the rim of the binding pocket (138).  
 Recent structural studies by Baron, et al. (136) show that multiple proteins contain 
conserved N-terminal sequences homologous to histone H3. These are often transcription 
factors that may function to hook LSD1 for recruitment to different genomic sites (136). 
Some examples include SNAI1 (related to morphogenetic events mediating tumor 
invasiveness), Ovo-like1 (epidermal proliferation and differentiation factor), SCRATCH1 
(nervous system specific), gfi1 (a gene repressor involved in hematopoiesis whose 
expression is regulated by LSD1-containing complexes), and insm1 (insulinoma-
associated 1; associated with differentiation of neural and pancreatic precursors; 
discovered in an neuroendocrine tumor) (136).  The SNAI1-LSD1 interaction has been 
crystallized and shows a similar binding mode to histone H3 (Figure 1.4) (136). Other 
binding partners dock on the tower domain; for example, another SANT-domain-
containing protein called MTA2 has also been shown to recruit LSD1 to chromatin as a 
member of the nuclear remodeling and deacetylase (NuRD) repressive complex, using a 
mechanism analogous to Co-REST (139). LSD1 has also been shown to be recruited by 
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the noncoding RNA HOTAIR into larger complexes containing PRC2 proteins (140). 
 Combinatorial regulation is commonly used to achieve the complex epigenetic 
functions that are required for differentiation and maintenance of cell- and tissue-specific 
gene expression programs. In addition to several interaction partners with H3-
homologous N-terminal tails, additional posttranslational histone modifications alter 
binding affinity of LSD1 for the H3 substrate, such that the histone code can drastically 
help or hinder LSD1 activity. At least 16 amino acids are required for functional 
demethylation, though the 21 amino acid substrate shows higher binding affinity (141). 
Many of the H3 residues 10-21 bind along the SWIRM/AOD boundary. Modifications 
here will affect binding affinity of the histone tail and change enzymatic efficiency. 
Closer to the histone binding pocket, many residues have been studied in detail. 
Methylation of Lys9 shows no effect on LSD1 activity, while acetylation of this residue 
shows a 6-fold decrease in binding affinity (141). LSD1 activity is completely abolished 
by phosphorylation at Ser10 (141).  Additionally, phosphorylation of H3T6 removes 
access to H3K4 and shifts the substrate specificity of LSD1 to H3K9 (142). 
 In addition to combinatorial regulation on the substrate histone tail, LSD1's 
function can be regulated by alternative splicing and posttranslational modifications. Two 
additional splice sites are observed in the KDM1A gene, one at exon 2 and exon 8 (143). 
The two additional splice sites may be incorporated either separately or together to result 
in three additional possibilities, either the 8a, 2a, or 8a/2a variants (143). The 2a variant 
results in a twenty amino acid insertion in the unstructured N-terminal region and may 
confer additional or altered specificity in recruiting other partners into chromatin-
remodeling complexes (143). The 8a variant is found only in neuronal tissue and contains 
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a four amino acid insertion at the base of the tower domain. This insertion contains a 
phosphorylation site at Thr396b that, when phosphorylated, acts as a dominant negative 
form of LSD1 that cannot bind CoREST or HDACs and fails to repress neuronal 
differentiation genes (143,144). Levels of 8a accumulate as neuronal development 
progresses and the loss of this variant results in decreased development of neuronal 
morphological features in vitro (143). The combined 8a/2a variant is found in the brain 
and testis (143). LSD1 has also been reported as a substrate for phosphorylation by 
protein kinase Cα (PKCα) (145) and protein kinase CK2 at Ser131, Ser137, and Ser166 
(146), though the function of these posttranslational modifications remains undetermined. 
  
1.3.4.2 An Epigenetic Effector with Context-Dependent Function 
 Based on the complexity of structural mechanisms which regulate LSD1 
enzymatic activity and its protein-protein interactions, it is unsurprising that the 
physiological function of LSD1 depends largely on both the cellular context and protein-
protein interaction partners. A few illustrative examples are described. At the most basic 
level, many LSD1/CoREST complexes contain BHC80, which recognizes and binds 
unmethylated H3K4 to prevent reactivation of target genes (147). Knockdown of BHC80 
results in de-repression of LSD1-repressed genes, so BHC80 might function to keep 
LSD1-containing complexes at the unmodified site for continued repression (147). This 
also builds on data from Forneris, et al. (141) suggesting that LSD1 requires a histone 
substrate relatively free of other posttranslational modifications and is the last actor 
during events which effectively switch the local chromatin state. However, while the 
most commonly studied LSD1-containing complexes are repressive, involve interaction 
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with CoREST and HDACs, and are targeted at H3K4, in complex with the androgen and 
estrogen receptors LSD1 shows specificity for H3K9 and demethylation activates 
hormone-receptor-dependent transcription (118,148).  
 Members of the Snai1 family recruit LSD1, through their H3 homologous 
Snail/Gfi (SNAG) domain, to the promoters of epithelial genes, like E-cadherin (CDH1). 
This is particularly important during the epithelial-to-mesenchymal transition (EMT) in 
order to repress the epithelial gene expression program and cellular phenotype (149-151). 
In malignant cells, the resulting cellular program drives cells to display a more invasive 
phenotype, and may partially explain the observed association of increased LSD1 
expression with aggressive tumor biology (149). 
 While it is relatively easy to envision the context-dependent function of LSD1 on 
a complex-to-complex basis, the most interesting data have demonstrated that LSD1 
exists in opposing complexes that co-localize in the nucleus. These complexes often exist 
at the boundaries between heterochromatin and euchromatin and are important for normal 
development (152,153). In drosophila, the LSD1 homolog dLsd1 and the histone 
demethylase Lid oppose each other at the boundaries of hetero- and euchromatin, with 
dLsd1 promoting the expansion of heterchromatic regions. Interestingly, both play a 
pivotal role in modulating Notch-dependent gene expression (154). dLsd1 is present at 
Notch target gene promoters and facilitates activation of transcription in antagonism of 
Lid when Notch signaling is on. However, when Notch signaling is off dLsd1 and Lid 
cooperate to repress Notch target genes (154). Based on the complex structural and 
biochemical factors that affect LSD1's specificity, this dual role is not unexpected, but the 
regulatory mechanisms that mediate these phenotypes in vivo remain poorly understood. 
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In another interesting example, LSD1 is critical for pituitary development (155). 
However, early development requires LSD1-mediated gene activation, while terminal 
differentiation events require LSD1-mediated gene repression at the same target genes 
(155); again, the precise mechanisms which determine the spatiotemporal regulation of 
LSD1 remain undetermined. 
 As a final note on substrate specificity, it should be noted that LSD1 is known to 
demethylate nonhistone substrates, though how LSD1 is targeted to these substrates is not 
understood. Demethylation of the p53 protein at Lys370 by LSD1 prevents the binding of 
p53 with 53BP1 that is required for p53-mediated transcriptional activation (156). Thus, 
LSD1 can repress p53 tumor suppressive function through methylation status of a single 
lysine residue. LSD1 is also critical for the maintenance of global DNA methylation 
levels in vivo through regulation of DNMT1 (157). Demethylation by LSD1 is required 
for DNMT1 protein stability and comprises a functional link between the histone and 
DNA methylation apparatus (157). Another interesting nonhistone substrate for LSD1 is 
metastatic tumor antigen 1 (MTA1), a member of both the NuRD repressive and 
nucleosome remodeling factor (NURF) coactivator complexes. When methylated, MTA1 
promotes formation of the NuRD complex, while demethylation by LSD1 induces a 
conformational change which promotes assembly of NURF complex components and 
switching function from transcriptionally repressive to transcriptionally activating (158); 






1.3.4.3 Challenges of Studying LSD1 Biology 
 The complexity of LSD1 biology presents obvious challenges to translate 
laboratory findings to the clinic. Whole-genome studies investigating TGFβ-induced 
EMT have shown that LSD1 is the critical regulator of decreased genomic H3K9me2 and 
increased H3K4me3 and H3K36me3 in a manner that may apply to malignant 
transformation (151). These types of findings speak to the potential power of specifically 
inhibiting LSD1 in cancer, but the biggest challenge remains understanding the 
underpinning of the biological mechanisms by which LSD1 acts. While the association of 
LSD1 with an aggressive clinical course has been established, LSD1 has also been 
reported to have some tumor suppressor function (139). 
 Target validation studies have traditionally used RNAi, MAO inhibitors, or 
polyamines to probe LSD1 biology in cancer.  In various cancer models, inhibition of 
LSD1 or RNAi-mediated knockdown resulted in increased H3K4 methylation, 
reexpression of aberrantly silenced tumor suppressor genes (127,159), decrease in 
prosurvival gene expression (127,160), differentiation of dedifferentiated cancer cell 
(124,128), and decreased cancer cell proliferation and survival 
(117,121,122,124,125,127-129,160). However, none of these modes of LSD1 inhibition 
represent ideal positive controls for novel compound development. Knockdown-rescue 
experiments have shown rescue of complex phenotypes in vivo with an enzymatically 
dead mutant (personal communication Michael Engel), and no published studies that the 
author could find attempted knockdown and rescue with both the wild-type and 
enzymatically dead constructs. LSD1 is present in complexes at thousands of gene 
promoters throughout the nucleus, but only enzymatically active at a smaller subset 
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depending on external stimuli (161). Global knockdown removes LSD1 and may affect 
the stability of multiple nuclear complexes independent of LSD1 enzymatic activity, 
confounding extrapolation of results to enzymatic inhibitors. The monoamine oxidase 
inhibitor most commonly used for target validation has been tranylcypromine, which is 
not potent or specific for LSD1, nor are the polyamines. Thus, deconvoluting which 
effects are on- vs. off-target with these treatments is challenging and holding novel 
classes of LSD1 inhibitors to display the same biological output as MAOi and 
polyamines may falsely discredit bonafide LSD1 inhibitors. This is supported by recent 
molecular modeling work suggesting that LSD1 has multiple binding pockets on its 
surface (162) coupled with results described in Chapter 2 which show different classes of 
LSD1 inhibitor displaying different biophysical effects on LSD1 protein in solution. One 
could envision disrupting both enzymatic activity and potentially protein-protein 
interactions through direct or allosteric mechanisms, and depending on the interaction 
disrupted the biological readout could be different. 
 The complexity of LSD1 biology and the factors confounding its exploration also 
make predicting toxicity difficult. LSD1 knockout is embryonic lethal (163) and it is an 
important regulator for normal developmental transcriptional programs in hematopoiesis 
(123), adipogenesis (164), and neurogenesis (165,166). LSD1 expression is highest 
during early development and has roles in maintaining pluripotency (167,168) and the 
cell cycle in stem cells (169) and initiating differentiation during development (170). 
Conditional knockdown of LSD1 in adult mice led to alterations in hematopoiesis 
characterized by an expanded progenitor compartment and decreased terminal 
differentiation (171). This phenomenon was recapitulated to varying degrees with 
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tranylcypromine and its derivatives, though small molecules were not tested in vivo 
(171). It is unknown what the therapeutic window would be for a potent LSD1 inhibitor 
in vivo, and whether differences would be observed for reversible and irreversible 
inhibitors. 
 
1.3.5 Pharmaceutics in Translational Science 
 In addressing the complexity of in vivo efficacy and toxicity of a novel epigenetic 
drug, translational scientists must exercise care in choosing an appropriate preclinical 
formulation. Primarily, the vehicle used for drug delivery and route of administration 
should not interfere in any way with evaluation of the biological system used for testing. 
Importantly, different stages of preclinical work place different constraints on the 
formulation used.  For example, in proof-of-concept studies the formulation scientist 
should maximize exposure within the limits of tolerability.  However, for 
pharmacokinetics studies, the formulation must provide detectable exposure without 
altering the properties of the test compound drastically. As a lead compound emerges and 
progresses toward the clinic, the formulations used must evolve to be more clinically 
relevant and acceptable to regulatory agencies. 
 While this may seem straightforward, the general solubility of new chemical 
entities evaluated is declining (172). Solubilizing agents which are acceptable in in vitro 
settings are poorly tolerated in vivo. Several alternative strategies can be used to 
overcome poor aqueous solubility and the appropriate solution is highly compound 
specific (173). For compounds which are weakly acidic or basic, pH adjustment using 
different buffering systems within the range of pH 2-9 can greatly improve aqueous 
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solubility. Another common strategy involves the use of cosolvents, though these have 
highly variable tolerability depending on the intended route of administration. Here 
organic molecules which are miscible with water provide nonpolar regions to interact 
with the solute.  Commonly used cosolvents include polyethylene glycol 400 (PEG400), 
propylene glycol, dimethylacetamide, ethanol, and dimethyl sulfoxide (DMSO).  Other 
strategies include co-complexation with cyclodextrins, which contain an interior non-
polar region for solute binding, and inclusion of lipids or surfactants, which can lead to 
micelle formation of other macromolecular complexes. Use of surfactants can also 
stabilize drug suspensions and facilitate drug uptake. In the studies reported herein, co-
solvent systems were the primary strategy for drug formulation, using guidelines 
previously reported to minimize confounding toxicities (173). 
 
1.4 Study Rationale and Objectives 
1.4.1 Rationale 
 Most studies of LSD1 biology to date have utilized either RNAi-mediated 
knockdown of LSD1, polyamine analogues, or tranylcypromine and its derivatives to 
investigate the biology of LSD1. These investigations suggest inhibition of LSD1 in 
cancer may provide benefit to some patients. However, these modes of LSD1 inhibition 
are neither potent nor specific, and even with well defined biological output, translation 
from mouse studies to the clinic remain difficult (174). More potent, specific, and 
reversible inhibitors of LSD1 are needed to carefully evaluate the biological impacts of 
LSD1 inhibition on global epigenomic regulation and tumorigenic phenotpes in in vitro 
and in vivo models of malignancy, identify biomarkers to guide clinical translation, and  
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assess the preclinical efficacy and toxicity of LSD1 inhibition. 
 Rationale: Reversible inhibitors with improved specificity and potency profiles 
can be used to perform proof-of-concept studies to validate LSD1 inhibition as a 
prospective therapeutic strategy in solid tumors. 
 
1.4.2 Hypothesis and Objectives 
 The primary objective of this work is to discover and evaluate a novel potent, 
specific, and reversible series of LSD1 inhibitors with physicochemical properties 
amenable for translation to the clinic. Our overarching hypothesis is that by targeting the 
key histone demethylase, potent and specific LSD1 inhibitors will exhibit single-agent 
efficacy in solid tumor models. In order to test this hypothesis, the first requirement is to 
discover and biochemically validate a series of novel LSD1 inhibitors, described in 
Chapter 2. The second requirement is to show that in malignancies sensitive to lead 
compound HCI2509, this efficacy translates to in vivo models of disease, described in 
Chapters 3 and 4. Critical aims and approaches are as follows: 
 
1.4.2.1 Chapter 2, Hypothesis 1 
A high-throughput virtual screening strategy can identify novel scaffolds which 1) 
show inhibitory activity in an enzymatic assay (goal IC50 < 1 μM) and 2) can be 
optimized to low nanomolar potency leads. 
 Approach: Identify a commercially available hit compound using high 
throughput virtual screening and followed by subsequent iterative biochemical 
testing and medicinal chemistry for hit-to-lead optimization. 
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1.4.2.2 Chapter 2, Hypothesis 2  
The novel lead compound will 1) show specificity over homologous enzymes, 2) bind 
LSD1 reversibly, 3) not compete with the histone H3 N-terminal substrate for LSD1, and 
4) show decreased cancer cell line viability. 
 Approach: Biochemically characterize the lead compound HCI2509 in an array 
of biochemical assays and assess the effect of HCI2509 on cancer cell line 
viability in vitro. 
 
1.4.2.3 Chapter 3, Hypothesis  
LSD1 inhibition with HCI2509 impairs function of the NuRD complex, causes global 
derepression of EWS/FLI repressed target genes, and shows antitumor activity in vivo 
across Ewing sarcoma cell lines. 
 Approach 1: Compare the global transcriptional profile of HCI2509 treatment 
against that of EWS/FLI- and EWS/ERG-knockdown and to validate selected 
findings across multiple cell lines. 
 Approach 2: In vitro characterization of HCI2509 treatment against other 
EWS/FLI-knockdown associated phenotypes, including cell morphology and 
oncogenic transformation. Additionally characterize global methylation changes 
caused by HCI2509 treatment. 
 Approach 3: Characterize LSD1 target engagement in cells through evaluation of 
the relationship between LSD1 inhibition, HMOX1 induction, and EWS/FLI 
function. 





1.4.2.4 Chapter 4, Hypothesis  
LSD1 inhibition with HCI2509 is an effective therapeutic strategy for malignancies 
with a more complex etiology, specifically Type II endometrial carcinoma. 
 Approach 1: Evaluate the effects of HCI2509 on proliferation, transformation, 
global histone methylation, and target gene derepression in hormone-resistant 
Type II endometrial carcinoma cell lines. 
 Approach 2: Test HCI2509 for in vivo antitumor efficacy using an orthotopic 
xenograft model of Type II endometrial carcinoma tracking disease with 
bioluminescence. 
These hypotheses and approaches, and the resulting data are discussed at length in their 
respective chapters. The results from Chapter 2 have been peer-reviewed and published in 
the Journal of Medicinal Chemistry. The studies described in Chapters 3 and 4 have been 
accepted at Clinical Cancer Research and submitted to BMC Cancer, respectively. 
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Table 1.1 FDA-approved epigenetic therapies. 
Agent Name 
(Trade Name) 




DNMT Myelodysplastic syndrome 2004 May 19 
Decitabine 
(Dacogen) 
DNMT Myelodysplastic syndrome 2006 May 2 
Vorinostat  
(Zolinza) 
HDAC Cutaneous T-Cell Lymphoma 2006 Oct 6 
Romidepsin 
(Istodax) 
HDAC Cutaneous T-Cell Lymphoma 2009 Nov 5 
 
Table 1.2 Histone methylation is globally misregulated in cancer. (Adapted from (104)) 
Cancer Type Methyl Mark Consequence 
Prostate Cancer ↓H3K4me2   High recurrence 
Prostate Cancer ↓H4K2me2   High recurrence 
Lung Cancer ↓H3K4me2   Poorer survival 
Kidney Cancer ↓H3K4me2   Poorer survival 
Breast Cancer ↓H3K4me2   Poorer survival 
Breast Cancer ↓H3K27me3 Poorer survival 
Breast Cancer ↓H4K20me3 Worse clinical outcomes 
Pancreatic Cancer ↓H3K4me2   Poorer survival 
Pancreatic Cancer ↓H3K9me2   Poorer survival 
Pancreatic Cancer ↓H3K27me3 Poorer survival 
Gastric Adenocarcinoma ↑H3K9me3   Poorer survival 
Ovarian Cancer ↓H3K27me3 Poorer survival 
Lymphomas ↓H4K20me3 Associated with 




Table 1.3 Altered expression of KDMs in cancer. (Adapted from (115)) 
Name Synonym Alteration Associated Cancer 
KDM1A LSD1, AOF2 Overexpression Prostate, neuroblastoma, 
lung, colorectal, bladder 
KDM1A LSD1, AOF2 Downregulation Breast 
KDM2B FBXL10, JHDM1B Overexpression Pancreatic, leukemia 
KDM2B FBXL10, JHDM1B Downregulation Glioblastoma 
KDM3A JMJD1A, JHDM2A Overexpression Colorectal, renal cell 
carcinoma 
KDM4A JMJD2A Overexpression Lung, breast 
KDM4B JMJD2B Overexpression ER + breast, bladder, lung 
KDM4C JMJD2C, GASC1 Amplification Esophageal, breast, 
medulloblastoma, primary 
mediastinal 
KDM4C JMJD2C, GASC1 Overexpression Lymphoma 
KDM5A JARID1A, RBP2 Overexpression Gastric, breast 
KDM5A JARID1A, RBP2 Translocation Acute myeloid leukemia 
KDM5B JARID1B, PLU1 Overexpression Breast, prostate, bladder, 
lung 
KDM5B JARID1B, PLU1 Downregulation Melanoma 
KDM6A UTX Mutation Multiple myeloma, 
esophageal squamous cell, 
renal cell, chronic 
myelomonocytic leukemia 
KDM6B JMJD3 Downregulation Lung, liver 















Figure 1.1 Histone methylation machinery. The histone methylation “writers” 
(methyltransferases; light gray) and “erasers” (demethylases; dark gray) for H3K4, 





Figure 1.2 The crystal structure of lysine-specific demethylase 1. LSD1 (blue) in 
complex with both Co-REST (yellow) and an N-terminal H3 peptide (magenta). FAD is 

























Figure 1.3 Catalytic oxidative demethylation of histone H3 lysine 4 by LSD1. 
Demethylation results in the generation of both H2O2 and formaldehyde. Adapted from 












Figure 1.4 Other proteins bind LSD1 through molecular mimicry. Comparison of SNAG 
domain (green) and histone H3 (magenta) binding to the LSD1 (blue) and CoREST 








HIGH-THROUGHPUT VIRTUAL SCREENING IDENTIFIES NOVEL 
N’-(1-PHENYLETHYLIDENE)-BENZOHYDRAZIDES AS 
POTENT, SPECIFIC, AND REVERSIBLEINHIBITORS  
OF LSD1 
 
Venkataswamy Sorna and Emily R. Theisen are co-first authors of this work. VS was 
responsible for the chemical synthesis and purification of the compound series. ERT 
wrote the manuscript and was responsible for biochemical assessment of HCI2509 as 
well as cell-based assays. Bret Stephens performed the initial compound screen of 121 
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2.8 Supplementary Materials 
2.8.1 Supplementary Methods 
2.8.1.1 Detailed Virtual Screening Methods 
2.8.1.1.1 Preparation of the Binding Site Model 
There were several X-ray crystal complex structures of LSD1 (PDB ID: 2Y48, 
3BAT, 3BAU, 2XAF,  2XAG, 2XAH, 2XAJ, 2XAQ and 2XAS) at the beginning of our 
work, we  used  the LSD1 complex model with an X-ray crystal structure (PDB code 
2Z5U) and protein coordinates used for fragment-based and structure-based virtual 
screening. Water molecules were then removed and the missing bond order and 
geometries were edited. Hydrogen atoms were added and the combined complex 
structure was submitted for protein preparation and energy minimization calculation 
using ICM and Schrodinger.  The fully refined structure with bound ligand molecule was 
further submitted for grids calculation to define the active site as the collection of amino 
acids enclosed within a 12 Å radius sphere centered on the bound ligand (Figure 2.1). The 
target LSD1was optimized using Monte Carlo simulation and energy optimizations.   
 
2.8.1.1.2 Preprocessing of three-dimensional ligand databases  
The external source database in the form of sdf format was processed using the 
ligand preparation tools. The final coordinates were stored in multi-sdf files. Custom 
filters included Lipinski's rule-of-five (Ro5) and manual filtering to remove very large 
molecules, dimers, polymers, molecules containing unusual heteroatoms, and highly 
reactive functional groups. Each of the databases were combined together with a final 
library of ~2 million molecules commercially available from 26 vendors were considered 
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for virtual screening using Glide SP/XP, ICM, and GOLD.   
 
2.8.1.1.3 Virtual Screening Method 
A flow scheme indicating the steps of the virtual screening (VS) process is shown 
in Figure 2.2. The database of 13 million library compounds was curated using Ligprep, 
the filters from Section 2.8.1.1.2, and Glide HTVS methods to attain the set of ~ 2 
million compounds screened against the prepared target. Grid potentials were rapidly 
generated which accounted for shape of the binding pocket, hydrophobicity, electrostatic 
potentials, and hydrogen-bonding profile. The compounds were screened using our own 
workflow (Figure 2.2) for LSD1 binding properties using a rigid target and flexible 
ligands in the internal coordinate’s space. The compounds experimentally confirmed as 
LSD1 inhibitors were used for regular docking into LSD1. Docking calculations of the 
LSD1 inhibitors were performed using the ICM and Glide docking module with default 
setup and rescoring with GOLD. The structures of the active compounds were energy 
minimized in the same environment and saved in PDB format. These energy-minimized 
inhibitors were then reposed into ICM and converted into ICM object, and MMFF 
charges were assigned for each of the ligand. Docking took an average of 3-4 
min/molecule on a four AMD 64-bit processors RedHat linux server with 4 GB of RAM. 







2.8.1.1.4 Postprocessing and Compound Selection Criteria 
 Compounds having desired scores, hydrogen bond formation and hydrophobic 
interactions were estimated by interatomic distances for further analysis.  The 
conformational stability of each candidate was also estimated by force field energy 
difference between the complexes conformation and freely minimized conformation, and 
the top-scoring candidates from this category were selected for further analysis. 
Compounds in each of the three categories were visually inspected to eliminate 
candidates without ideal hydrogen bond geometry, hydrophobic molecular surfaces, or 
torsion angles.  The resulting 121 focused screening structures were further analyzed 
using molecular property filters in QikProp, with calculated log S, permeability (Caco2 
and MDCK) and Lipinski like criteria. 
 
2.8.2 Analytical Data for Purchased Hits 
The commercially available hit compounds given in Table 1 (1-10) were 
purchased from ChemBridge, http://www.hit2lead.com, and Enamine, 
http://www.enamine.net. Their characterizations were confirmed using 1H NMR and 
Mass Spec and their purity was determined by HPLC. 
 (E)-4-hydroxy-N'-(2-hydroxybenzylidene)benzohydrazide (1): 1H NMR (400 
MHz, DMSO-d6): δ 11.84 (s, 1H), 11.39 (s, 1H), 10.11 (s, 1H), 8.54 (s, 1H), 7.87 
(m, 2H), 7.49 (d, 1H, J = 8.4 Hz), 7.28 (t, 1H, J = 8.4 Hz), 6.91 (m, 4H). ESI-MS: 
256.2 [M+H]+. 
 (E)-N'-(5-chloro-2-hydroxybenzylidene)-4-hydroxybenzohydrazide (2): 1H NMR 
(400 MHz, DMSO-d6): δ 11.89 (s, 1H), 11.32 (bs, 1H), 10.04 (s, 1H), 8.57 (s, 
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1H),7.82 (m, 2H), 7.61 (d, 1H, J = 2.4 Hz), 7.29 (dd, 1H, J = 2.4 & 8.8 Hz), 6.95 
(d, 1H, J = 8.4 Hz), 6.88 (m, 2H). ESI-MS: 290.7 [M+H]+.  
 (E)-4-hydroxy-N'-(1-(2-hydroxyphenyl)ethylidene)benzohydrazide (3): 1H NMR 
(400 MHz, DMSO-d6): δ 10.94 (s, 1H), 10.03 (bs, 1H), 7.84 (m, 2H), 7.62 (dd, 
1H, J = 1.6 & 8.0 Hz), 7.29 (t, 1H, J = 8.4 Hz), 6.90 (m, 4H), 2.47 (s, 3H). ESI-
MS: 270.28 [M+H]+.  
 (E)-4-bromo-N'-(2-hydroxybenzylidene)benzohydrazide (4): 1H NMR (400 MHz, 
DMSO-d6): δ 12.01 (s, 1H), 11.15 (s, 1H), 8.62 (s, 1H), 7.88 (m, 2H), 7.75 (m, 
2H), 7.53 (d, 1H, J = 8.8 Hz), 7.31 (t, 1H, J = 8.8 Hz), 6.93 (m, 2H). ESI-MS: 
319.16 [M+H]+.   
 (E)-3-chloro-N'-(2-hydroxybenzylidene)benzohydrazide (5): 1H NMR (400 MHz, 
DMSO-d6): δ 12.09 (s, 1H), 11.12 (s, 1H), 8.64 (s, 1H), 7.98 (s, 1H), 7.90 (m, 
1H), 7.67 (m, 1H), 7.57 (m, 2H), 7.31 (t, 1H, J = 7.6 Hz), 6.93 (m, 2H). ESI-MS: 
274.70 [M+H]+.   
 (E)-N'-(1-(2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide 
(6): ESI-MS: 403.4 [M+H]+, purity by HPLC 97.25%. 
 (E)-3-(morpholinosulfonyl)-N'-(1-(naphthalen-1-yl)ethylidene)benzohydrazide 
(7): ESI-MS: 437.5 [M+H]+. 
 5-chloro-N'-(2-fluoro-5-(morpholinosulfonyl)benzoyl)-2-methoxybenzohydrazide 
(8): 1H NMR (400 MHz, DMSO-d6): δ 7.90 (m, 3H), 7.51 (m, 2H), 7.22 (m, 1H), 
4.02 (s, 3H), 3.71 (m, 4H), 2.97 (m, 4H). ESI-MS: 471.8 [M+H]+. 
 N'-(3-chlorobenzoyl)-2-fluoro-5-(morpholinosulfonyl)benzohydrazide (9): 1H 
NMR (400 MHz, DMSO-d6): δ 8.01 (m, 2H), 7.92 (m, 2H), 7.53 (m, 3H), 3.69 
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(m, 4H), 2.96 (m, 4H). ESI-MS: 441.8 [M+H]+. 
 (E)-N,N-diethyl-3-(2-(1-(p-tolyl)ethylidene)hydrazinecarbonyl)benzenesulfon- 
amide (10): ESI-MS: 387.5 [M+H]+, purity by HPLC 94%. 
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 Supplementary Table S2.1. Docking scores of compounds 1-10 
S. 
No 





-42.25 -8.14 56.26 
2 
 
-42.25 -7.92 58.21 
3 
 
-21.91 -7.87 51.29 
4 
 
-37.77 -8.64 57.69 
5 
 
-36.3 -8.84 47.98 
6 
 
-24 -6.26 43.26 
7 
 
-20.97 -6.14 46.64 
8 
 
-18.39 -6.63 49.93 
9 
 
-8.16 -7.21 41.86 
10 
 
-8.5 -6.81 52.19 
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>100 -16.89 -4.87 27.21 
12 
 
>100 -16.34 -4.89 29.21 
13 
 
>100 -16.21 -4.76 24.21 
14 
 
>100 -21.21 -5.27 28.23 
15 
 
12.2 -17.22 -5.12 18.21 
16 
 
18.6 -26.81 -6.96 28.21 
17 
 
67.3 -27.28 -5.23 29.81 
18 
 











































































0.196 -42.25 -8.14 56.26 
31 
 
22 -27.29 -6.77 31.55 
32 
 
>100 -21.89 -6.69 32.31 
33 
 
>100 -13.29 -6.86 39.03 
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>100 -22.95 -6.29 37.19 
35 
 
37 -21.38 -7.22 25.94 
36 
 





















>100 -16.43 -5.16 22.74 
41 
 
>100 -19.99 -6.16 21.04 
42 
 
>100 -16.19 -4.42 20.17 
43 
 
>100 -17.23 -5.66 20.61 
44 
 
>100 -13.87 -3.33 24.82 
45 
 
>100 -11.81 -5.77 22.76 
46 
 
>100 -17.99 -5.99 22.52 
77 
 















>100 -14.39 -4.96 20.12 
48 
 
>100 -53.29 -4.77 22.61 
49 
 
>100 -17.64 -4.52 25.21 
50 
 
>100 -17.31 -4.86 23.78 
51 
 
>100 -21.28 -7.33 30.22 
52 
 
>100 -19.73 -4.97 31.55 
53 
 
>100 -17.34 -3.59 22.31 
54 
 
>100 -20.21 -6.76 39.03 
55 
 
>100 -26.29 -5.23 37.19 
56 
 
>100 -26.25 -6.22 35.94 
57 
 
67 -21.28 -6.66 39.93 
58 
 
>100 -19.33 -6.33 32.14 
59 
 
>100 -29.84 -5.67 25.65 
78 
 















>100 -16.23 -4.19 25.92 
61 
 
>100 -11.97 -3.16 19.22 
62 
 
>100 -14.27 -3.17 20.71 
63 
 
18 -21.88 -4.42 22.23 
64 
 
>100 -17.13 -4.22 22.07 
65 
 
>100 -16.55 -5.13 26.62 
66 
 
>100 -17.11 -4.37 30.49 
67 
 
>100 -19.39 -2.79 33.71 
68 
 
>100 -16.87 -4.69 31.58 
69 
 
32 -21.88 -3.17 30.98 
70 
 
>1 uM -24.43 -6.52 30.62 
71 
 
>1 uM -23.94 -6.33 30.97 
72 
 
>1 uM -21.41 -7.23 31.28 
79 
 















>1 uM -21.99 -9.47 32.23 
74 
 
>1 uM -26.25 -8.99 35.26 
75 
 
>1 uM -29.18 -7.79 36.75 
76 
 
>1 uM -24.23 -7.17 30.42 
77 
 
>1 uM -23.37 -7.43 38.68 
78 
 
>1 uM -21.81 -7.46 30.59 
79 
 
>1 uM -26.54 -7.13 30.29 
80 
 
>1 uM -26.45 -8.17 35.82 
81 
 
>1 uM -27.31 -8.21 38.72 
82 
 
>1 uM -26.99 -7.06 31.62 
83 
 
>1 uM -26.35 -6.20 30.01 
84 
 
>10 uM -28.18 -6.42 31.67 
84 
 
>10 uM -22.33 -8.93 31.27 
86 
 
>10 uM -26.39 -8.13 34.82 
87 
 
>10 uM -31.96 -6.17 30.89 
88 
 
>10 uM -29.64 -6.86 31.04 
80 
 















>10 uM -21.75 -7.36 33.14 
90 
 
>10 uM -29.81 -7.77 32.02 
91 
 
>10 uM -26.79 -7.44 33.02 
92 
 
>10 uM -32.55 -8.16 33.69 
93 
 
>10 uM -19.28 -6.29 34.21 
94 
 
>10 uM -25.66 -7.67 31.48 
95 
 
>10 uM -21.77 -8.16 37.94 
96 
 
>10 uM -23.61 -7.16 33.75 
97 
 
>10 uM -29.59 -7.97 30.41 
98 
 
>10 uM -29.435 -8.89 32.92 
99 
 
>10 uM -31.41 -6.16 33.19 
100 
 
>10 uM -31.89 -.923 32.41 
101 
 
>10 uM -36.29 -7.87 34.16 
102 
 
>10 uM -24.19 -7.22 33.67 
81 
 















>10 uM -27.11 -7.66 34.92 
104 
 
>10 uM -22.17 -7.17 31.97 
105 
 
>10 uM -32.77 -6.95 31.62 
106 
 
>10 uM -36.74 -6.16 30.52 
107 
 
>10 uM -36.75 -6.14 30.65 
108 
 
>10 uM -31.56 -7.27 41.62 
109 
 
>10 uM -21.87 -8.19 31.56 
110 
 
>10 uM -34.21 -8.79 32.61 
111 
 
>10 uM -39.88 -8.29 33.41 
112 
 
>10 uM -34.13 -7.42 37.79 
113 
 
>10 uM -33.39 -6.76 32.73 
114 
 





-16.44 -4.19 21.99 
116 
 
>10 uM -24.21 -7.39 32.08 
82 
 















>10 uM -29.78 -6.49 35.05 
118 
 
>10 uM -24.43 -6.41 30.12 
119 
 
>10 uM -23.89 -7.99 32.45 
120 
 
>10 uM -21.29 -6.16 22.08 
121 
 
>10 uM -16.74 -5.19 25.05 
83 
 
Supplementary Table S2.3. Tanimoto similarity coefficients comparing compound 12 
and known LSD1 inhibitors from Chart 1 
 



















Supplementary Table S2.4. Off-target inhibition assay results. 
 
[12] (nM) 
Activity % ± SD 
 CYP1A2 CYP2C19 CYP2C9 CYP2D6 CYP3A4 hERG 
30000      98±4 
10000 60±3 53±1 46±2 94±2 21±2 104±2 
3333 86±1 91±2 84±1 101±11 46±2 100±6 
1111 87±2 105±0.4 98±3 102±10 71±4 102±7 
370 96±1 111±3n/a 108±0.2 105±12 87±10 98±3 
123 97±8 110±0.1 111±1 110±8 100±3 95±4 
41.2 93±3 107±12 107±5 105±12 98±9 98±2 
13.7 105±7 114±1 109±1 108±6 98±1 107±0.1 
4.57 106±4 106±11 107±8 104±12 99±9 93±2 
1.52 111±3 117±3 112±1 109±6 105±1 100±2 
0.51 110±2 89±3 107±6 106±2 96±5  
       
 D-LDH GO     
100000 103±7 105±3     
30000 103±6 106±3     
10000 106±5 108±6     
3000 112±5 92±3     
1000 121±6 97±0.3     
300 118±5 109±3     
100 119±5 102±1     
 
Supplementary Table S2.5. Different model fits for enzyme kinetics results. 
 
Model Competitive Noncompetitive Uncompetitive 
vmax (F/s) ± SE 635.8±12.83 688.9±10.80 695.8±11.67 
Km (μM) ± SE 0.919±0.1128 1.310±0.0928 1.411±0.1042 
ki (nM) ± SE 4.136±0.7027 39.04±3.046 32.76±2.67 
DMSO R2 0.9033 0.9269 0.9275 
1 nM R2 0.8788 0.8774 0.8758 
3 nM R2 0.9022 0.9077 0.9076 
10 nMR2 0.8492 0.9154 0.9060 
30 nM R2 0.2257 0.9289 0.9146 
100 nM R2 -0.6184 0.6953 0.5652 























Supplementary Figure S2.1. Binding Site Model and definition of active site of LSD1 





















Supplementary Figure S2.2. Flow diagram for the Virtual Ligand Screening (VLS) 






































REVERSIBLE LSD1 INHIBITION INTERFERES WITH 
GLOBAL EWS/ETS TRANSCRIPTIONAL ACTIVITY 





Savita Sankar and Emily R. Theisen are co-first authors of this work. SS and ERT 
executed RNA-seq studies with HCI2509. SS profiled EWS/ETS knockdown by RNA-
seq. SS and ERT jointly analyzed sequencing data. SS and ERT generated EWS/ETS 
knockdown constructs to assay the cell viability shift. ERT performed viability 
experiments with EWS/FLI expressed in NIH3T3cells. SS performed qPCR validation of 
target genes. Laura M. Hoffman stained, imaged, and analyzed cells by 
immunofluorescence microscopy. SS and ERT performed soft agars. ERT performed 
apoptosis assays. Timothy Mulvihill performed global methylation analysis. SS, ERT, and 
TM peformed HMOX1 analysis. ERT and Jared Bearss wer responsible for xenograft 




Reproduced with permission from Sankar S and Theisen ER, et al. Clinical Cancer 
Research 2014 20 (17), 4584-4597.  



































































 Supplementary Table S3.1. Primer Sequences for qRT-PCR analysis from RNA. 
Gene Forward Reverse 
NKX2-
2 
5’ CTACGACAGCAGCGACAACC 3’ 5’ GCCTTGGAGAAAAGCACTCG 3’ 
CAV1 5’ ATCGACCTGGTCAACCGCGAC 3’ 
5’ CGAAGTAAATGCCCCAGATGA 
3’ 
E2F1 5’ GCCACTGACTCTGCCACCATA 3’ 
5’ GGTGGGGAAAGGCTGATGAAC 
3’ 
IGF1 5’ GAAGATGCACACCATGTCCTC 3’ 5’ CTCCAGCCTCCTTAGATCACA 3’ 
GSTM4 5’ GCTGCCCTACTTGATTGATGG 3’ 5’TGATTGGAGACGTCCATAGCC 3’ 
HMOX
1 
5’ AACTTTCAGAAGGGCCAGGT 3’ 5’ GTAGACAGGGGCGAAGACTG 3’ 
IGFBP3 5’ CATCAAGAAAGGGCATGCTAA 3’ 5’ CTACGGCAGGGACCATATTCT 3’ 
CDH1 5’ TGCCCAGAAAATGAAAAAGG 3’ 5’ GTGTATGTGGCAATGCGTTC 3’ 






Supplementary Figure S3.1. Transcriptional Profiling of HCI2509 in A673 and TTC-
466. (A,B) Cell viability assay showing the difference in HCI2509 sensitivity between 
(A) TTC-466 cells with control and EWS/ERG knockdown or (B) NIH 3T3 cells with 
control and EWS/FLI expression. The dose-response curves were determined after 96 
hours of treatment and normalized to the vehicle controls. n=3 for each point. Error bars 
denote standard deviation. EC50 and 95% CI were determined using GraphPad Prism 6. 
Note the line for ERG-RNAi data in (A) is a connecting line, not a curve fit. (C) Venn 
diagram representations of the overlap between the EWS/FLI and EWS/ERG 
transcription profiles, both generated by RNA-seq. Chi-square determined p-values are 
indicated with the observed contingency tables shown. (D) Gene set enrichment analysis 
(GSEA) using genes regulated by EWS/FLI in A673 cells (RNA-seq) as the rank-ordered 
dataset and the EWS/ERG-upregulated or the EWS/ERG-downregulated genesets (RNA-
seq). Normalized enrichment scores (NES) and p-values are shown. (E,F) Venn diagram 
representations generated from respective RNA-seq data sets using default cutoffs (2-fold 
change, FDR=10%).  (E) represents the overlap between the HCI2509 and the EWS/FLI-
knockdown transcription profiles, both generated in A673 cells; (F) the overlap between 
the HCI2509 and the EWS/ERG-knockdown transcription profiles, both generated in 
TTC-466 cells. Chi-square determined p-values are indicated with the observed 
contingency tables shown. (G,H) GSEA using genes directly regulated by EWS/FLI in 
A673 cells (ChIP-chip and RNA-seq overlap) as the geneset and  HCI2509 regulated 
genes in A673 cells (RNA-seq) as the rank-ordered dataset in (G) or the vorinostat 
regulated genes in A673 cells (microarray) as the rank-ordered dataset in (H). Normalized 
enrichment scores (NES) and p-values are shown. (I,J) Top ten categories from DAVID 
functional analysis of the (I) EWS/FLI up-/HCI2509 down- and EWS/FLI down-
/HCI2509 upregulated genesets and (J) EWS/ERG up-/HCI2509 down- and EWS/ERG 
down-/HCI2509 upregulated genesets. The log transformed enrichment scores for each 
category are indicated on the x-axis. (K) Validation of NKX2.2, CAV1, GSTM4, E2F1, 
IGF-1, RUNX2, IGFBP3, HMOX1 and CDH1 as HCI2509 targets by qRT-PCR analysis 
using EWS-502, SK-ES-1, SK-N-MC, and TC-71 cells treated for 48 hours with vehicle 
or HCI2509 at 2xEC50. The p-value for each fold change is < 0.05 (n=3). Individual p-



























Supplementary Figure S3.2. Morphological changes with HCI2509 treatment (A) 
Whole-field immunofluorescence images of A673 cells treated with increasing doses of 
HCI2509 for 72 hours. Staining was performed for F-actin stress fibers (red – phalloidin) 
and for focal adhesions (green – paxillin), and nuclei (blue). HCI2509 induced a dose-
dependent increase in the cell spreading and morphology. (B,C) Immunofluorescence 
images of A673 cells treated with either control siRNA or LSD1 siRNA 50 nM for 48 
hours. Staining was performed for (B) LSD1 and (C) F-actin stress fibers. Measurements 
of LSD1 nuclear signal and cell area were performed on at least 6 fields for each 
transfection. Decrease in LSD1 nuclear signal correlated with more organized actin fibers 
and cell spreading. (D) Whole-field and (E) close up immunofluorescence images of 
TTC-466 cells treated with increasing doses of HCI2509 for 3 days. Staining was 
performed for F-actin stress fibers (red – phalloidin) and for focal adhesions (green – 
paxillin), and nuclei (blue). HCI2509 induced a dose-dependent increase in the cell 
spreading and morphology. (F) Measurement of cell area in pixels in phalloidin images 
shows a dose-dependent increase in cell spreading with of HCI2509. TTC-466 cells were 
fixed and stained with phalloidin. Cell area was quantified as previously described (39). 
Data is shown as scatter plot with mean plus standard deviation, and unpaired parametric 








Supplementary Figure S3.3. Effects of HCI2509 on Transformation, Methylation, and 
Apoptosis. (A,B,C) Quantification of colonies formed by (A) EWS-502, (B) TC71, and 
(C) SK-ES-1 cells treated with either vehicle (0.3% DMSO) or varying doses of 
HCI2509. Error bars indicate SD of duplicate assays. EC50 values were determined using 
GraphPad Prism 6. (D,E,F) Cell viability and caspase activation at 0, 24, and 48 hours in 
(D) SK-N-MC, (E) TC71, and (F) SK-ES-1 cells treated with 2xEC50 HCI2509. 
Measurements were normalized to their respective vehicle (0.3% DMSO) sample at the 











Supplementary Figure S3.4. Regulation of HMOX1 in Ewing sarcoma. (A) qRT-PCR 
for HMOX1 induction following treatment with candidate LSD1 inhibitors with respect 
to inhibitor biochemical potency against LSD1 in a biochemical assay (Cayman 
Chemical). (B) Western blot analysis to demonstrate expression of the RNAi-resistant 3x-
FLAG tagged EWS/FLI, Δ22, or R2L2 cDNA constructs using an anti-FLAG antibody in 
A673 cells expressing a control shRNA (Luc) or an EWS/FLI shRNA. Tubulin was used 
as the loading control. (C)  qRT-PCR analysis to assess level of knockdown of various 
corepressors or HMOX1 induction in A673 cells treated with either Luc-RNAi or RNAi 
for REST (REST p=3.53E-6, HMOX1 p=1.92E-2), RCoR1 (RCoR1 p=1.18E-4, HMOX1 
p=3.67E-2), NCoR/SMRT (NCoR/SMRT p=2.60E-7, HMOX1 p=5.85E-1), or Sin3A 
(Sin3A p=1.27E-6, HMOX1 p=1.57E-1). Error bars indicate SD and p-values were 
determined using students t-test (n=3). (D) Western blot analysis for HMOX1 expression 
in A673 cells infected either with empty vector or an HA-tagged HMOX1 cDNA using an 
anti-HMOX1 antibody. Tubulin was used as a loading control.(E) Growth assays (3T5) 
for A673 cells described in (D). Student’s t-test showed no significant difference in 
growth curves. (F) Quantification of colonies formed by A673 cells described in (D). 









Supplementary Figure S3.5. Tumor volume, body weight and blood counts. (A) In vivo 
subcutaneous hind-flank xenograft studies measuring tumor volume for animals bearing 
tumors grown from (A) SK-ES-1 cells. The p-value was determined by 2-way ANOVA 
comparing the treatment curve to the vehicle curve. Individual tumor growth curves are 
shown for the vehicle-treated (blue) and HCI2509-treated (red) groups. (B,C,D) Body 
weight measurements for animals bearing tumors grown from (B) A673 cells, (C) SK-N-
MC cells, and (D) SK-ES-1 cells. N=10 for all groups, with the exception of SK-N-MC 
HCI2509 treated group as noted. For body weights, the change in body weight 
normalized to day 0 was considered and a student’s t-test was used to determine the p-
value. (E) Blood counts for white blood cells (WBC), hematocrit (HCT), and platelets 
(PLT) from immunodeficient mice treated intraperitoneally either with vehicle or 40 
mg/kg HCI2509 MWF for 24 days ± SD.  Blood was drawn using a cheek draw and 







REVERSIBLE INHIBITION OF LYSINE SPECIFIC DEMETHYLASE 1 
IS A NOVEL ANTITUMOR STRATEGY FOR POORLY 




Emily Rose Theisen and Snehal Gajiwala performed the experiments and wrote the 
manuscript. Jared Bearss provided insight in experimental design. Sunil Sharma and 
Margit Janat-Amsbury designed and supervised the experiments and wrote the 
manuscript. Venkataswamy Sorna and Margit Janat-Amsbury contributed reagents, 
















Reproduced with permission from Theisen ER, et al. BMC Cancer 2014, 14:752.  













































































Supplementary Figure S4.1. Time course evaluation of cell cycle perturbations caused 
by HCI2509 treatment. (A,B) Cell cycle populations of (A) AN3CA and (B) KLE cell 
lines after exposure to vehicle (0 and 48 hours) or 3 μM HCI2509 (6, 12, 24, and 48 
hours). For AN3CA and KLE cells, 2 x 104 counts and 1 x 104 counts were used, 





















Supplementary Figure S4.2. TUNEL assay replicates and controls. (A,B) Fluorescence 
microscopy images of (A) AN3CA and (B) KLE cell lines after exposure to either vehicle 
or 3 X IC50 HCI2509 and then stained with TUNEL for apoptotic nuclei (green), DAPI 
for nuclei (blue), and phalloidin for actin (red). HCI2509 treatment induced apoptosis 
with apoptotic cells marked with (*). (C) Fluorescence microscopy images of TUNEL 
negative and positive controls with untreated AN3CA and KLE cells.  Negative controls 
were generated by adding labeled nucleotide with no enzyme and positive controls were 
generated by pretreating DNase before TUNEL labeling. Cells are stained with TUNEL 





















Supplementary Figure S4.3. In depth xenograft model analysis. (A) Individual mouse 
images from study day 7 (day 0 of treatment). All images are on the same luminescence 
scale from 1.54 x 104 p/s to 8.66 x 106 p/s. (B) Quantified bioluminscence measurements 
of both the vehicle and HCI2509 treatment groups pooled. Total flux (photons/second) 
was rank ordered and plotted on a semilog plot. The linearity of the log-transformed data 
supports a log-normal distribution. (C) Fisher's exact test shows significant association of 
HCI2509 treatment with tumor regression. Both the observed and expected contingency 
tables are shown with the reported p-value. (D) Tumor volume and body weight 
measurements including both the untreated and unimplanted control. Tumor volumes are 
plotted as the geometric mean of the observed luminescent signal and body weight is 















 This work described the discovery of a novel N’-(1-phenylethylidene)- 
benzohydrazides compound series as potent, specific and reversible LSD1 inhibitors. Hit-
to-lead optimization identified HCI2509 as a lead compound with nanomolar binding 
affinity for LSD1. HCI2509 is a noncompetitive LSD1 inhibitor with no detectable 
activity against either of the monoamine oxidases or other tested flavoenzymes. 
Treatment with HCI2509 decreased viability across numerous cancer cell lines. The 
overarching purpose of this work was to address the hypothesis that by targeting the key 
histone demethylase, potent and specific LSD1 inhibitors will exhibit single-agent 
efficacy in solid tumor models. We chose both Ewing sarcoma and endometrial carcinoma 
as model systems to test this hypothesis with HCI2509. 
 
5.1.1 High-throughput Virtual Screening Leads to HCI2509 
 This work started with a high-throughput virtual screen of approximately 2 
million small molecules against the crystal structure of LSD1 (PDB ID: 2Z5U). The 
compound library used was built with commercially available small molecules pre-
filtered for favorable physicochemical properties. An initial hit, compound 1 in Chapter 
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2, was identified and showed LSD1 inhibition with a biochemical IC50 of ~100-300 nM. 
Compound 1 was then optimized through iterative medicinal chemistry and biochemical 
testing to arrive at HCI2509 (“compound 12” in Chapter 2) which has a Ki of ~30 nM. 
The hit to lead optimization process improved the specificity profile of the  N’-(1-
phenylethylidene)-benzohydrazides series considerably. Compound 1 showed activity 
against MAO B comparable to that of the MAO inhibitor tranylcypromine, while 
HCI2509 showed no detectable activity against either MAO A or B. HCI2509 was shown 
to be a noncompetitive inhibitor that perturbed LSD1 conformation in a manner distinct 
from tranylcypromine. The protein purification optimized to support these studies is 
reported in Appendix A. While the binding site of HCI2509 is predicted to fall in or near 
the FAD binding pocket of LSD1 based on the docking setup used, no evidence has been 
gathered to date which shows FAD displacement. This work showed little off-target 
activity against the cytochrome P450 enzymes as well as human Ether-à-go-go (hERG). 
Importantly and finally, HCI2509 showed activity in cell-based assays, with two 
additional and unpublished cell-line panels reported in Appendix B. These results 
informed the decision to test HCI2509 in Ewing sarcoma and endometrial carcinoma. 
 
5.1.2 HCI2509 is Uniquely Active in Ewing Sarcoma 
 HCI2509 showed particularly potent activity in multiple Ewing sarcoma cell lines. 
LSD1 was recently discovered as critical for EWS/FLI-mediated target gene repression 
through recruitment as a member of the NuRD complex (1). We hypothesized that 
through reactivation of EWS/FLI-repressed tumor suppressors, we were inducing 
apoptosis and impairing transformation in Ewing sarcoma cell lines.  In order to test this 
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we looked at the transcriptional changes induced by HCI2509 treatment by RNA-
sequencing and compared them to the transcriptional changes caused by EWS/FLI 
knockdown in the same cell line. We found that not only was HCI2509 disrupting 
EWS/FLI-mediated repression globally, but that it also impaired EWS/FLI-mediated 
transcriptional activation of critical oncogenes. This effect was observed at both direct 
and indirect target genes, and contrasted with HDAC inhibition with vorinostat, which 
only affected the EWS/FLI-repressed targets. The effect was so striking that we next 
asked whether or not it was specific to EWS/FLI, or whether HCI2509 would show 
comparable effects in a cell line containing and alternative EWS/ETS fusion, specifically 
EWS/ERG. We found the same phenomena where HCI2509 treatment disrupted the 
global EWS/ERG transcriptional program both at activated and repressed target genes. 
This was also the first time that the EWS/ERG transcriptional profile was published and, 
while unsurprising, it was observed that both EWS/FLI and EWS/ERG regulated similar 
transcriptional programs. 
 We further hypothesized that these transcriptional changes would be consistent 
across cell lines. Most Ewing sarcoma cell lines tolerate EWS/FLI knockdown poorly as 
compared to A673 cells and RNA-sequencing experiments are costly in both time and 
money. We thus performed qPCR after treatment with HCI2509 in several cell lines to 
assess the transcriptional changes in a 9-gene panel representing characteristic EWS/FLI 
target genes and saw consistent downregulation of EWS/FLI activated targets and vice 
versa across Ewing sarcoma cell lines. 
 Ewing sarcoma kills patients after relapse and metastasis. The cellular 
morphologies associated with Ewing sarcoma metastasis have been characterized by 
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Chaturvedi, et al. (2) and show that EWS/FLI most likely promotes metastatic 
phenotypes through decreased cellular adhesion, though not through migration and 
invasiveness. This mechanism is different from epithelial cancers, and so while it does 
not involve the epithelial-to-mesenchymal transition that LSD1 helps to regulate (3-5), 
we wanted to evaluate the effects in the same in vitro morphology assay used in (2). 
HCI2509 and siRNA-mediated knockdown of LSD1 both recapitulated the EWS/FLI 
knockdown phenotype here and HCI2509 prevented transformation in colony forming 
assays, confirming that LSD1 inhibition reverses some of the cellular phenotypes driven 
by EWS/FLI as would be predicted by the transcriptional profiling. 
 This was also the first study to demonstrate target engagement in cells, though 
indirectly, through HMOX1 induction. LSD1 was found associated with the HMOX1 
promoter and siRNA-mediated knockdown of LSD1 showed dose-dependent increases in 
HMOX1 transcript. HMOX1 was of interest, because not only is it repressed by EWS/FLI 
and activated by HCI2509, but it is also downregulated in primary patient samples (6). 
This suggests that LSD1 inhibition may prove relevant to the transcriptional mechanism 
at work in human patients. Interestingly, even with target engagement demonstrated, the 
changes in global methylation at LSD1 substrates H3K4 and H3K9 were more subtle 
than anticipated in both the A673 and TTC466 cell lines. No significant changes were 
observed at H3K4, though H3K9me2 and H3K9me3 both significantly increased. A 
mechanistic understanding is yet to be determined. 
 Most importantly, LSD1 inhibition with HCI2509 showed single-agent antitumor 
efficacy in multiple Ewing sarcoma xenograft models. These models are notoriously 
difficult to carry out, as tumors typically show a wide range of growth rates, and are 
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likely log-normal distributed in this manner.  However, HCI2509 showed a clear effect in 
all three models tested, with two complete regressions observed, and no observed 
toxicity. These data are extremely promising, as few treatment options work as single 
agents in mouse models of Ewing sarcoma, and they suggest a therapeutic window may 
be wide enough in this disease. 
 
5.1.3 Antitumor Activity of HCI2509 in Endometrial Carcinoma 
 Having shown both target engagement and ruled out a nonspecific cytotoxic 
mechanism of action, we wanted to test whether HCI2509 would also show efficacy in a 
second malignancy also associated with epigenetic misregulation, though perhaps 
through more diverse mechanisms than a single translocation. Type II endometrial 
carcinoma was recently shown to commonly have driver mutations in chromatin 
regulatory enzymes, and was also sensitive to LSD1 inhibition in our cell-line screens 
with HCI2509. In this model system, LSD1 inhibition showed decreased proliferation 
and transformation in two cell lines that were refractory to hormone treatment. LSD1 
inhibition caused perturbation of the cell cycle, though the mechanisms through which 
this occurs remain undetermined.  
However, unlike Ewing sarcoma cell lines, H3K4me3 was significantly 
upregulated with HCI2509 treatment, and H3K9me2 varied between cell lines. HCI2509 
induced HMOX1 and the adhesion gene CDH1, further supporting that the proliferation, 
transformation, and cell cycle effects were the result of LSD1 target engagement. 
Significantly, LSD1 inhibition induced apoptotic cell death. We chose to pursue the 
question of in in vivo efficacy with the KLE cell line in an orthotopic model.  Type II 
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endometrial cancer is commonly disseminated in the peritoneal cavity and subcutaneous 
models simply cannot recapitulate this tumor environment. Epigenetics represents the 
intersection of the genes with the environment and in a disease driven by genes, 
environment, and epigenetics, evaluation of an epigenetic therapy requires testing in the 
most representative system feasible. In this model system of endometrial cancer, 
HCI2509 treatment was significantly associated with tumor regression, demonstrating 
single agent efficacy. 
 
5.1.4 Noteworthy Observations 
 Taken together, this body of work both supports epigenetic therapy as a powerful 
tool in the treatment of cancer and underscores the amount of work left to be done in 
order to fully understand the mechanistic basis for therapeutic efficacy. For example, the 
EWS/ETS-based activity seen in Ewing sarcoma suggests LSD1 may act in a manner that 
is Ewing sarcoma specific. While the precise mechanisms are the topic for future studies, 
this particular instance is proof-of-concept that in at least some malignancies, epigenomic 
misregulation is so central to the disease etiology that it may prove feasible to hijack the 
whole oncogenic program. Ewing sarcoma is unique, however, in being relatively 
mutationally silent at onset (7), such that malignant reprogramming happens exclusively 
through epigenomic mechanisms. In other malignancies, we need better tools to identify 
which patients might benefit from particular epigenetic therapies. While LSD1 is broadly 
observed to be upregulated across dedifferentiated cancers, which perhaps hints at a 
common role in malignancy, it should be noted that the changes to global histone 
methylation with HCI2509 were markedly different in Ewing sarcoma and endometrial 
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carcinoma. Each disease will likely have its own etiology requiring deep sequencing 
experiments to fully grasp. However, some progress is being made, with SOX2 
overexpression suggested as a biomarker denoting sensitivity to LSD1 inhibition in lung, 
breast, and ovarian carcinomas (8). 
 Another interesting observation not fully discussed in Chapters 2-4 is the fact that 
while both Ewing sarcoma and endometrial carcinoma showed in vitro sensitivity which 
translated in vivo, this is not true for all cell lines. In fact, the PC3 cell line showed very 
little sensitivity in the cell line screens up to 3 μM (Appendix B), but was exquisitely 
sensitive in xenograft models when the plasma concentrations were consistently 200-400 
nM (9). Further, this is consistent with drug development efforts in GlaxoSmithKline's 
LSD1 inhibitor program. Similarly insensitive cell lines in vitro show delayed tumor 
growth in xenograft models (10). The reasons for this remain unclear, but are likely 
related to poor correlation between in vitro culture conditions and the in vivo tumor 
microenvironment and how these signals are integrated at the epigenomic level. It also 
underscores the importance of well-designed in vivo studies which recapitulate the 
disease state as can best be achieved before human trials as the differences between mice 
and men are certainly as large as that between plastic and an immunodeficient mouse. 
 
5.2 Future Studies 
 While on the whole the studies reported here show significant promise for LSD1 
inhibitors as they progress to and through the clinic, several lines of inquiry became 
apparent as a result of this work. There are important questions to be asked from both a 
basic and translational perspective to build an understanding of the causal relationships 
143 
 
by which LSD1 drives cancer and how different modes of inhibition may impair those. 
This will enable more precise clinical science to get the right LSD1 inhibitor to the right 
patient as LSD1 inhibition reaches the clinic. 
 
5.2.1 Biophysical and Biochemical Inquiries 
 Several biochemical questions remain unanswered, the most obvious of which is, 
is there a better way to show LSD1 binding within cells, preferably direct binding? A 
recently reported technique utilizing an in-cell version of the thermal shift assay 
(CETSA) (11) for binding may provide the answer. In essence, this assay calls for drug 
exposure either in cell lysates or whole cells. After equilibration, the lysates or cells are 
incubated at temperatures varying from 40-64°C, at which point cells are lysed if 
necessary. Protein which has unfolded and crashed out is then removed by centrifugation 
and the protein of interest is detected in the supernatant by western blot.  The antibody 
used needs to be fairly sensitive and specific for the protein of interest. Ultimately, 
similar to the fluorescent thermal shift assay used in Chapter 2, the readout for binding is 
increased amounts of protein at higher temperatures than the vehicle control, to 
demonstrate the stabilizing effect of ligand binding. The most immediate follow on 
question is whether or not the compound binds any other proteins in the cell. This would 
require synthesis of a biotinylated derivative and confirmation that biotinylation does not 
completely abolish binding affinity. Any proteins that pull down with the compound 
could be further confirmed with CETSA. 
 The real elephant in the room is the binding mode of HCI2509. Given the 
complexities of LSD1 regulation discussed in Chapter 1, knowing the binding pocket 
144 
 
would enable the generation and testing of point-mutants, which should rescue enzymatic 
activity in the context of drug exposure. It would also identify potential mechanisms for 
the development of resistance. LSD1 has been crystallized in a number of hands (12-16) 
and in collaboration with the Chris Hill lab; crystallography is possible, though not 
required for clinical translation. 
 
5.2.2 Further Routes of Inquiry in Ewing Sarcoma 
 LSD1 inhibition in and the epigenomics of Ewing sarcoma are major areas of 
research that remain incompletely explored, but show great promise. At a basic level, the 
histone methylation data reported in Chapter 3 comprise a crude and preliminary 
evaluation of the epigenetic impacts of LSD1 inhibition in Ewing sarcoma cells. Really, 
the “epigenetics” of HCI2509 in Ewing sarcoma are not yet worked out in mechanistic 
detail and the observed changes in global histone methylation marks are quite subtle. In 
order to understand what changes, and whether these changes are associated with 
EWS/FLI or LSD1 requires a minimum of directed ChIP studies at candidate loci, but 
more likely ChIP-seq for the histone marks of interest, LSD1 and EWS/FLI in the 
absence or presence or drug or various knockdowns. The very first questions to address 
are the genomic co-localization patterns of EWS/FLI and LSD1, specifically at active 
targets, as well as the sites of histone methylation mark changes in the context of drug 
treatment. 
 Other pieces of data show different transcriptional effects with different classes of 
LSD1 inhibitors. The irreversible inhibitors and HCI2509 appear to both modulate 
HMOX1 in a dose-dependent fashion around the cell viability IC50, which supports 
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HMOX1 as a bonfide LSD1 target. They both leave NR0B1 unaffected. Interestingly, the 
EWS/FLI activated gene NKX2.2 is downregulated by HCI2509 and the EWS/FLI-
repressed CTGF is upregulated by HCI2509, but not the irreversible inhibitors (Figure 
5.1). This is where identification of the binding mode and relevant protein-protein 
interactions partners would be potentially illuminating. Given that the binding mode is 
unknown and that LSD1 is bound, two possibilities exist, either there is something 
unknown about LSD1 biology or there is an unknown off-target effect, or both, and that 
these unknowns are particularly impactful in Ewing sarcoma. The next step is to test 
other potent and reversible inhibitors for the same transcriptional activity.  
 While the discussion in Chapter 1 of positive controls for novel modes of LSD1 
inhibition still applies, it is worth investigating whether knockdown of LSD1 by siRNA 
or shRNA recapitulate the transcriptional and other effects of HCI2509 in Ewing sarcoma 
cells by RNA-seq, morphology assessments, colony forming assays, and tumorigenic 
studies. Optimization of siRNA in Chapter 3 showed a 50% reduction in LSD1 protein 
levels as the maximum knockdown attainable. If LSD1 is as critical as the inhibition data 
would suggest, it may be difficult to optimize a system with 80-90% knockdown of 
LSD1. Moreover, if an shRNA can be optimized, to what extent do different LSD1 
mutants, for example, enzymatically dead or truncated, rescue LSD1 knockdown? 
Answers to these questions would help map the relevant domains on LSD1 for more 
mechanistic biochemical studies to clarify the role of LSD1 in Ewing sarcoma.  
 As mentioned, metastasis and recurrent disease are the killers in Ewing sarcoma, 
and the xenograft studies reported in Chapter 3 address only primary subcutaneous 
tumors. Intratibial models were used by Chaturvedi, et al. (2) to investigate the metastatic 
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behavior of Ewing sarcoma cells. Investigation of HCI2509 treatment in intratibial 
models of both mice and rats may prove useful in understaning the impact of LSD1 
inhibition on the development of metastatic disease. Preliminary studies in nude rats 
show drastic differences in the development of metastases between vehicle and HCI2509 
treated animals (Figure 5.2). The lung metastases in Figure 5.2 were undetectable using 
bioluminsecent imaging, such that optimization of a different imaging modality is 
required. 
 Both CTGF and HMOX1 were observed to be downregulated in primary patient 
samples of Ewing sarcoma and upregulated with HCI2509 treatment. As was reported in 
Chapter 3, secreted proteins were significantly upregulate by HCI2509. IL8 is another 
secreted protein similarly downregulated by EWS/FLI and observed to be decreased in 
patient samples, and upregulated by HCI2509. TGFβR2 was validated as a tumor 
suppressor gene repressed by EWS/FLI, both in cell lines and the clinic, and was also 
induced by HCI2509 treatment (1). The continued optimization of animal models 
provides an opportunity to explore the pharmacodynamics of secreted proteins, such as 
IL8 or CTGF, which may correlate with pharmacological modulation of HMOX1 or 
TGFβR2 levels in tumor samples. 
 In addition to response biomarkers, in order to translate LSD1 inhibition to the 
clinic for Ewing sarcoma, the use of HCI2509 needs to be assessed in combination with 
the other standards of care. This is required both in vitro and in vivo to evaluate the 
potential for drug synergy, antagonism, or unforeseen toxicity.  The most likely 
candidates for these studies are irinotecan and temozolomide. Preliminary data from an 
SK-ES-1 xenograft model suggest that HCI2509 may show synergistic effects in 
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combination with temozolomide and larger studies are required to validate these results in 
other models of the disease (Figure 5.3). 
 All in all, the results reported in Chapter 3 represent a major advance in our ability 
to target EWS/ETS-mediated oncogenic transcriptional programs. It has pushed forward 
in a way that raises several fundamental basic science questions to address the 
mechanisms by which one small molecule can flip a switch recently thought unflippable 
with such strategies. Moving toward the clinic will likewise require efforts to develop 
appropriate preclinical models to truly test in animals what we hope to test in the clinic in 
order maximize the predictive value of preclinical work. Ewing sarcoma is a rare disease 
that affects young adults, and any human trial in this population needs to be as tightly 
designed as possible to determine whether this could provide better therapeutic options 
for this aggressive malignancy. 
 
5.2.3 Further Routes of Inquiry for Endometrial Carcinoma 
 Given the promising results both in vitro and in vivo in endometrial carcinoma, 
several follow up studies are warranted. From the perspective of basic LSD1 biology, it is 
interesting, though perhaps not unexpected, that the observed changes in global histone 
methylation are different in endometrial cancer than those shown for Ewing sarcoma. 
Moreover, the two cell lines tested showed slightly different global histone methylation 
changes in response to HCI2509 exposure, notably H3K9me2 increased in AN3CA cells 
while remaining unchanged in KLE cells. The biological mechanisms driving this 
difference may provide insight about the varying role of LSD1 in different cell lines and 
differentiate which phenomena are most associated with the antitumor effects of 
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HCI2509. Testing this pharmacodynamic marker for LSD1 inhibition across more 
endometrial carcinoma cell lines, both Type I and Type II, could shed further light on the 
impact of HCI2509 on global histone methylation in endometrial cancer, and allow 
analysis of whether changes in any one mark predict sensitivity to HCI2509.  It would 
also be helpful to know how global epigenetic changes translate to transcriptional 
changes in endometrial carcinoma, such that RNA-seq and ChIP-seq similar to those 
proposed for Ewing sarcoma should be pursued. Further, validation that LSD1 inhibition 
phenocopies siRNA-mediated LSD1 knockdown would strengthen this work, though this 
approach needs to be undertaken with careful consideration due to the complexities of 
LSD1 biology, described in Chapter 1. 
 Translating this work to the clinic will required addressing whether the antitumor 
efficacy observed across cell lines also holds true in multiple xenograft models, including 
those derived from primary tumor tissue. Additionally, HCI2509 should be screened for 
synergy both in vitro and in vivo with the current standards of care. Pretreatment with 
HCI2509 for 24 hours showed no sensitization to progesterone in vitro for AN3CA or 
KLE (Figure 5.4), though this may not be true for other Type II endometrial carcinoma 
cell lines or models of Type I disease. Overall, the data reported for Type II endometrial 




One of the major remaining hurdles for translation of this compound series to the 
clinic is the optimization of a more clinically acceptable formulation. The relative 
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hydrophobicity (logP=3.96) and high melting temperature (>220°C) of HCI2509 classify 
the compound as “brick dust.” Moreover, the hydrazone core is amenable to a relatively 
planar conformation and contains several hydrogen bond donors and acceptors for inter-
and intramolecular hydrogen bonding. Together, these factors contribute to drive 
HCI2509 to form needle-like crystals in aqueous formulations. Ideally, translation to the 
clinic would involve the development of an oral formulation or tablet.  This would likely 
require the development of an amorphous form or salt, as well as inclusion of surfactants 
or wetting agents to promote dissolution. The hydrazone moiety also necessitates the use 
of enteric coating to prevent acid-catalyzed hydrolysis of the compound. 
Taken together, these factors have limited the available preclinical formulation 
strategies. Salt formation has been attempted multiple times by Venkataswamy Sorna to 
no avail. Ultimately, we utilized several different cosolvent strategies for the preclinical 
studies reported here, with both stable solutions and suspension tested in pharmacokinetic 
studies. Efficacy studies utilized a stable suspension of HCI2509 crystals dosed 30 mg/kg 
directly into the peritoneal cavity. There are different features of Ewing sarcoma and 
endometrial carcinoma to consider in the design of formulations to enable future studies 
in these diseases.  Ewing sarcoma requires systemic treatment to target metastatic and 
micrometastatic disease as adjuvant therapy in concert with surgical resection. Oral 
tablets or intravenous routes of delivery would be appropriate.  However, while 
metastatic endometrial cancer may benefit from a similar strategy, in cases where the 
disease remains localized to the peritoneal cavity or uterus, delivery via intravaginal gel 
may offer an attractive alternative route.  This type of localized delivery minimizes the 
risk of off-target systemic toxicities or undesirable epigenetic reprogramming.  Further, a 
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vaginal gel might be formulated to contain varying combinations of agents which show 
synergistic effect, for example, progesterone therapy. Varying the formulation strategy for 
the same epigenetic agent could tailor the desired epigenetic reprogramming effects to the 
specific needs of the disease of interest. 
 
5.3 Outlook 
 The overarching goal of this lab is to provide cancer patients with innovative 
targeted therapeutic options. This project addressed that larger goal through the 
identification and validation of a novel series of potent, specific, and reversible LSD1 
inhibitors, both biochemically and in preclinical models of cancer. Ultimately the  N’-(1-
phenylethylidene)-benzohydrazides series of inhibitors have cast new light on the biology 
of Ewing sarcoma that may lead to improved clinical care for this rare and aggressive 
disease through both translational and basic research. Additionally, the compound series 
identified herein showed single agent efficacy in Type II endometrial cancer, suggesting 
epigenetic inhibition may provide therapeutic benefit in this aggressive gynecologic 
malignancy. Detailed mechanistic studies are still required in both disease areas to fully 
elucidate the biological role for LSD1 and the mechanism by which HCI2509 acts. 
 HCI2509 faces many hurdles on the road to the clinic. While HCI2509 is highly 
permeable, solubility remains a major challenge. Either analogues more amenable to salt 
formation or possessing more favorable solubility characteristics would be preferable for 
additional preclinical studies and clinical development. Candidate derivatives are 
currently under investigation at the Center for Investigational Therapeutics and remain a 
promising topic for future study. Until then, HCI2509 is a useful tool for proof-of-
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concept and mechanistic studies in both in vitro and in vivo model systems and will 
inform the clinical development and use of novel reversible LSD1 inhibitors for Ewing 
sarcoma, endometrial carcinoma, and other malignancies. 
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Figure 5.1 The effects of different classes of LSD1 inhibitors on EWS/FLI targets. 
(A,B,C) The change in gene expression of EWS/FLI-activated targets NKX2-2 and 
NR0B1 and EWS/FLI-repressed targets HMOX1 and CTGF induced by (A) HCI2509, (B) 
the irreversible inhibitor OG-L002 (biochemical IC50 ~ 20 nM), and (C) tranylcypromine 
(biochemical IC50 ~ 20 uM). A673 cells were treated with varying concentrations of 
inhibitor for 48 hours before RNA was harvested. Doses were chosen based on  the IC50 
of the inhibitor in a 96-hour cell viability assay such that the dose range is centered 
around the IC50. HCI2509 results in decreased expression in NKX2-2, no effect on 
NR0B1, and dose-dependent increasesd in CTGF and HMOX1, consistent with the result 
in Chapter 3. Interestingly, both other LSD1 inhibitors are much less potent at decreasing 















                     
 
 
Figure 5.2 HCI2509 decreases metastasis in a nude rat model of Ewing sarcoma. A dose 
5 x 106 SK-N-MC cells were implanted in the tibia of nude rats (n=6) and allowed to 
engraft for 7 days. At that time the primary tumor was imaged by bioluminescence and 
animals were randomized into vehicle or treatment groups. Treatment animals received 
daily intraperitoneal injections of 60 mg/kg of HCI2509. After 4 weeks of treatment, 
animals were taken off of the study and monitored. Thirty days later, rats were sacrificed 
and lung metastases were observed in vehicle-treated animals, while very little metastatic 
















                   
 
 
Figure 5.3 Potential synergy between HCI2509 and temozolomide in vivo. In a 
subcutaneous hindflank SK-ES-1 xenograft study of HCI2509 dosed with vehicle (n=10), 
50 mg/kg HCI2509 (n=10), 25 mg/kg temozolomide (n=10), or a combination (n=10) 
orally showed potential synergistic activity between HCI2509 and temozolomide.  The 
tumor model displays a fair amount of variability, such that error bars were removed for 










                                    
 
Figure 5.4 HCI2509 does not sensitize cells to treatment with medroxyprogesterone 17-
acetate (MPA). (A,B) AN3CA (A) and KLE (B) cells were pretreated with varying 
concentrations of HCI2509 for 24 hours before being treated with either mock or 10 µM 
MPA for an additional 72 hours. Controls included vehicle (0.5% DMSO) and vehicle 
treatment for 24 hours followed by 10 µM MPA for an additional 72 hours (MPA alone). 
Overall, KLE cells were slightly affected by MPA, but no additive effects are observed in 













A.1 Protein Purification Protocol: Full Length LSD1 
 
Transform BL21*(DE3) cells with pET15b-hLSD1 (Amp resistance) and allow 
colonies to grow overnight at 37°C. Innoculate 5 mL of LB+Amp with one colony and 
allow to grow at 37°C+shaking until OD600~0.6-1.  Innoculate 50 mL of LB+Amp with 
desired amount of previous culture to grow at 37°C+shaking overnight.  In the morning, 
take 6 mL for every liter of induction media to innoculate and centrifuge at 3000 rcf for 
20 minutes.   
Innoculate 1L of LB+Amp with desired amount of bacteria and grow until culture 
reaches  OD600~0.8-0.9.  Induce expression with 0.5 mM IPTG and reduce temperature to 
22°C and rpm to 180. Shake for 20 hours and then collect pellets. 
Thaw pellet halfway in cold running water and the remaining halfway on ice.  
Once thawed, add 1 mg/mL lysozyme and Dnase (optional).  Sonicate to lyse 7 cycles of 
[45 seconds on, 1 minute off].  Clean sonicator tip between tubes/beakers to improve 
lysis of later samples. 
Ultracentrifuge lysate at 40K rcf, 4°C, for 45 minutes and discard supernatant. 
Resuspend pellet in His Extraction Buffer. Ultracentrifuge lysate at 40K rcf, 4°C, for 45 
minutes and collect supernatant. Equilibrate column by rinsing off with His-B Buffer 
followed by His-A Buffer. Run supernatant over desired His column to load protein.  
Instead, wash with His-A Buffer until back to baseline.  Elute with a 15-20 column 
gradient.  Collect appropriate fractions. 
Dialyze eluent into TGEK-50 depending on your final goal (you may need to 
concentrate your sample after dialysis; I would just do two size exclusion runs and 
combine everything). Ultracentrifuge dialyzed protein at 40K rcf, 4°C, for 45 minutes 
160 
 
and collect supernatant. Equilibrate S-column (S) with TGEK-1000 and -50 (1000 and 50 
mM KCl, respectively). Run protein over ion exchange column and elute with a salt 
gradient over 15-20 columns.   
Dialyze ion exchange eluent into TGEK-300. Equilibrate size exclusion column in 
the TGEK-300. Ultracentrifuge dialyzed protein at 40K rcf, 4°C, for 45 minutes before 
running size exchange.  Collect appropriate fractions for use, concentrate in stirred cell if 
desired, aliquot, and flash freeze. Typical yield ~1 mg or less/L. 
 
A.2 Buffers 
A.2.1 His Extraction Buffer 
 25 mM Tris  
 1 M NaCl 
 0.1 mM EDTA 
 10 mM Imidazole 
 +Fresh BME (7 uL per 100 mL buffer) and PMSF (0.5 mM) 
 
A.2.2 His A Buffer 
 25 mM Tris  
 1 M NaCl 
 0.1 mM EDTA 
 10 mM Imidazole 




A.2.3 His B Buffer 
 25 mM Tris  
 1 M NaCl 
 0.1 mM EDTA 
 500 mM Imidazole 
 +Fresh BME (7 uL per 100 mL buffer) and PMSF (0.5 mM) 
 
A.2.4 T/CGEK 
(For T/CEK do not add glycerol)  
 T=tris (pH~7) C=citrate (pH~5.2) 
 25 mM T or C 
 10% glycerol (G) 
 1 mM EDTA (E) 
 desired concentration of KCl 







Figure A.1 Chromatography tracking LSD1 purifcation. The columns on the first gel are 
as follows: 1=ladder, 2=lysate loaded onto column, 3=flow through, 4-10=discarded 
elution fractions during imidazole gradient, 11-12=fractions containing LSD1 band at 96 
kDa, 13=ladder. The columns on the second gel are as follows: 14=ladder, 15=loaded 
sample, 16=collected fractions, 17=concentrated final product, 18=positive control from 





Figure A.2 Purified protein is active. Confirmation of active enzyme using the Michaelis-













B.1 96-Cell Line Panel 
Table B.1 A 96-cell line panel. Ninety-six cell lines were assayed for decreased cell 
viability by ATP-Lite after 96-hours of HCI2509 treatment. 
 
Cell Line IC50 (µM HCI2509) Malignancy 
SK-ES-1 0.47 Ewing's sarcoma 
NCCIT 0.47 embryonal teratoma 
Raji 0.49 B-Lymphocyte; Burkitt's 
Lymphoma 
S-16  Schwann cells 
Ramos 0.52 Lymphoblastoid 
U-937 0.55 Macrophage; histiocytic 
lymphoma 
H647 0.57 metastatic adenosquamous 
lung carcinoma 
Skov-3 0.65 ovarian adenocarcinoma 
MCF-7 0.66 metastatic breast 
adenocarcinoma 
BT-20 0.77 mammary gland; carcinoma 
RL-95-2 0.78 uterine endometrial 
carcinoma 
LNCap 0.78 prostate carcinoma 
AN3-CA 0.73 uterine endometrial 
adenocarcinoma 
Her-218 0.62 breast 
C-6 0.74 glioma 
TC-32 0.85 Ewing's sarcoma 
A673 0.93 Ewing's sarcoma 
Hs-B2 0.99 Leukemic t-cell 
Jurkat 0.93 T-cell 
SaOS-2 0.89 osteosarcoma 
LOX 0.90 malignant melanoma 
BT-549 1.05 mammary gland ductal 
carcinoma 
Hep-G2 0.94 hepatocellular carcinoma 
H1666 0.97 colorectal carcinoma 
F98 0.99 glioma 
EWS-502 0.92 Ewing's sarcoma 
Hs700-T 0.93 Pancreatic 
MV4-11 0.97 biphenotypic B 
myelomonocytic leukemia 
AGS 0.92 gastric adenocarcinoma 
C-33A 1.11 cervical carcinoma 
Ovcar-8 0.85 ovary 
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Table B.1 Continued   
Cell Line IC50 (µM HCI2509) Malignancy 
Hs578-T 1.15 Breast 
Kato-III 1.06 gastric carcinoma 
Capan-1 1.07 liver met of panc primary 
U251 1.19 glioblastoma 
K562 1.22 chronic myelogenous 
leukemia 
HL-60 1.05 acute promyelocytic 
leukemia 
MDA-MB-468 1.17 breast carcinoma 
Molt-4 1.10 acute lymphoblastic 
leukemia 
RD-ES 1.25 Ewing's sarcoma 
HeLa 1.22 cervical adenocarcinoma 
Hec-1-A 1.25 uterine endometrial 
adenocarcinoma 
T98-G 1.19 glioblastoma multiforme 
Colo-205 1.29 colorectal adenocarcinoma 
Hs-B2 1.33 T-lymphoblastic leukemia 
Su-DHL6 1.32 B-cell 
HPAF-2 1.40 Pancreas 
Kasumi -1 1.27 AML 
KG-1 1.27 AML 
A2780 1.10 Ovarian carcinoma 
HCT-116 1.13 Colorectal carcinoma 
HT-29 1.20 colorectal adenocarcinoma 
BxPc-3 1.20 Pancreas adenocarcinoma 
SK-MEL-5 1.27 melanoma 
Hel 1.46 Bone-erythro leukemia 
U87-MG 1.73 Glioblastoma-astrocytoma 
Yugen-8 1.15 metastatic melanoma 
MG-63 1.59 osteosarcoma 
TC-71 1.42 Ewing's sarcoma 
MDA-MB-231 1.50 Metastatic breast 
adenocarcinoma 
AsPc-1 1.55 Metastatic pancreatic 
adenocarcinoma 
RKO 1.74 Colorectal carcinoma 
J82 1.68 bladder carcinoma 
Malme-3M 1.74 malignant melanoma 
H1781 1.89 NSCLC 
IOMM-1 1.68 malignant meningioma 
PSN-1 1.74 pancreatic adenocarcinoma 
HCT-15 1.77 colorectal carcinoma 
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Table B.1 Continued   
Cell Line IC50 (µM HCI2509) Malignancy 
SW-480 1.60 colorectal adenocarcinoma 
Hs822-T 1.96 Ewing's sarcoma 
MiaPaCa-2 2.10 pancreatic carcinoma 
A498 2.20 kidney carcinoma 
OPM-2 2.51 myeloma 
Caki-1 1.83 kidney carcinoma 
HPAC 2.38 pancreatic adenocarcinoma 
Wi-58 2.56 Normal Lung 
786-0 2.28 renal adenocarcinoma 
Du-145 2.45 brain met of prostate 
SK-UT-1 2.34 uterine sarcoma 
SK-MEL-2 2.62 melanoma 
PC-12 2.88 adrenal 
phaeochromocytoma 
H460 2.39 Large cell lung carcinoma 
Panc-1 2.19 pancreatic carcinoma 
Mut-J 2.39 pancreatic 
H1975 2.89 NSCLC 
H522 2.94 NSCLC 
SNU-16 1.78 gastric cancer 
A549 2.65 lung carcinoma 
Hek-293 2.27 Embryonic kidney 
Hs-766-T 2.41 Metastatic pancreatic 
adenocarcinoma 
MDA-MB-435 2.81 Melanoma 
H441 2.80 lung papillary 
adenocarcinoma 
PC-3 2.82 Bone met of prostate 
CFPAC-1 3.16 Pancreas 
Hup-T4 2.67 Pancreatic adenocarcinoma 






B.2 xCELLigence Profiling 
 
Figure B.1 xCelligence screen of Ewing sarcoma cell lines. Real-time measurement of 
cellular index in four Ewing sarcoma cell lines after treatment with 0.3% DMSO (blue), 
300 nM HCI2509 (purple), 1 µM HCI2509 (green), or 3 µM HCI2509 (red) following 24 
hours of cell seeding. Measurements were taken every 2 hours. Data are presented as 
mean and standard deviation (n=3).These data were used to pick the appropriate dose and 
timing for many experiments reported in Chapter 3, specifically RNA-seq. Cellualr index 
is a measure of electrical impedance of current passed through the media caused by the 
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Emily R Theisen and Jared Bearss performed the animal dosing, plasma collection, 
extraction, and sample preparation. Adam Hollerbach of the Department of Chemistry 
Mass Spectrometry Core designed and optimized the mass spec detection protocol. 
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C.1 Mass Spectrometry Methodology 
 
C.1.1 Quantitation of HCI-2509 in Rat and Mouse Plasma 
 
C.1.1.1 Preparation of HCI2509 Stock Solution 
 
 Prepare stock solution of 1.25 mg/mL HCI2509 in DMSO. Add 40µL of stock 
solution to 960µL of plasma, to make a 50.0 μg/mL spiking solution.   
 
















25,000 50.0 200 200 400 
18,750 50.0 150 250 400 
12,500 50.0 100 300 400 
5,000 50.0 50 450 500 
2500 50.0 20 380 400 
1250 50.0 10 390 400 
500 5.00 50 450 500 
250 5.00 20 380 400 
125 5.00 10 390 400 
50.0 0.500 40 360 400 
25.0 0.500 20 380 400 




C.1.1.3 Preparation of HCI2528 (Compound 14 Chapter 2) Stock 
 
 Make a stock of 1.25 mg/mL HCI-2528 (internal standard) in DMSO.  Add 10µL 
of stock solution to 1990µL of DMSO, to make a 6.25 μg/mL spiking solution.   
 
C.1.1.4 Sample Preparation  
 All samples should be kept on ice until processing. Pipette 50µL of blank plasma 
(double blank and blank), standard, or subject sample into a 1.5mL microcentrifuge tube. 
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Add 5µL of internal standard to each tube except double blank.  Prepare a tube with just 
serum and the internal standard as a control. Add 150µL acetonitrile and vortex 
vigorously for 60 seconds. Centrifuge at top speed for 5 minutes in refrigerated centrifuge 
set to 4ºC. Pipette 150µL water into a separate 1.5mL microcentrifuge tube. Add 150µL 
supernatant (top layer) from the extract and vortex vigorously for ~10 sec. Store samples 
and standard curve at -20ºC until analysis. 
 
C.1.1.5 Liquid Chromatography Parameters 
Waters ACQUITY H-CLASS 
 
 Column: Waters Xbridge C18 3.5 um, 4.6x50mm 
 
 Solvent C Name: Formic Acid 
 
 Solvent D Name: Acetonitrile 
 
 Low Pressure Limit: 0 psi 
 
 High Pressure Limit: 15000 psi 
 
 Seal Wash Period 5.00 min 
 
 Gradient:  
 
Time (min) Flow Rate (mL/min) %C %D Curve 
1. Initial  1.000   60.0 40.0 Initial 
2. 1.00  1.000   60.0 40.0 6 
3. 2.50  1.000   00.0 100.0 6 
4. 4.00  1.000   60.0 40.0 6 




C.1.1.6 Mass Spec Parameters 
 
Waters ACQUITY TQD 
 




 Source Temperature (°C)  100 
 
 Desolvation Temperature (°C) 215 
 
 Cone Gas Flow (L/Hr)  5 
 
 Desolvation Gas Flow (L/Hr) 550 
 




C.1.1.7 MRM Parameters 
 
Compound Parent (m/z) Daughter (m/z)  Dwell (s)     Cone (V)     Col (V) 
HCI-2528 396.1  168     0.100 30  23 








 Mice were dosed by intravenous tail injection (IV) or by oral gavage (PO) with 
HCI2509. At the desired time point mice were sacrificed and blood was collected by 
cardiac puncture. Plasma was then stored at -80 ºC until analysis. Formulations for 5mg/kg 
IV and 20 mg/kg PO dosing were stable solutions. Formulations for 50 mg/kg PO and 40 
mg/kg IP were stable suspensions of HCI2509 crystals which were administered through 
a 22 ½ gauge needle. 
 Generally speaking, in mice, HCI2509 appears to be rapidly cleared (Cl=24.33 
ml/min/kg) with a half-life of 0.87 hour. The bioavailability of HCI2509 from oral 
formulations varied depending on whether the form was a solution and a suspension.  The 
solution form (F=27%) showed much greater bioavailability than the suspension 
(F=4.5%), consistent with high predicted permeability for HCI2509 and related 
173 
 
compounds. In the case of the suspension, the low bioavailability is likely due to the 
stability of HCI2509 crystals as they pass through the GI tract. The acid lability of the 
hydrazone moiety likely decreases the observed F for both oral forms. Efficacy studies 
utilized a suspension dosed intraperitoneally, which provided a depot for release of drug 
out to 4 hours. 
 
C.2.1.1 Formulations 
C.2.1.1.1 5 mg/kg IV and 20 mg/kg PO – Clear, Yellow Solution 
 15% N,N-dimethylacetamide 
 20% Propylene glycol 
 25% Water for injection 
 40% Polyethylene glycol 400 MW 
 
C.2.1.1.2 50 mg/kg PO – Stable, Crystalline Suspension 
 10% Ethanol 
 40% Propylene glycol 
 50% Phosphate-buffered saline (pH 7.4) 
 
C.2.1.1.3 40 mg/kg IP – Stable, Crystalline Suspension 
 50% PEG400 
 50% PBS 
 Drug was completely dissolved in PEG400 using sonication and PBS added. 
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Table C.1 Pharmacokinetic parameters for 5 mg/kg HCI2509 dosed as solution IV. 
Parameter  
Time (hr) Cp HCI2509 (ng/ml) 
 
 
Mice 1-8 Mice 9-16 Mice 17-24 Mean STDEV %CV 
0.08333 7391 8228 6338 7319 947 12.9 
0.25 3251 2578 3797 3209 610 19.0 
0.5 1374 1768 1589 1577 197 12.5 
1 655 414 891 653 239 36.5 
2 119 88 235 147 77.5 52.6 
4 0 24 35 19.7 17.9 91.0 
8 0 17 12 9.67 8.74 90.4 
24 0 0 0 0 0 
 
       C0  
(ng/mL) 11143.85 14698.90 8188.44 11343.73 3259.83 28.7 
AUC0-t  
(ng*hr/mL) 3131.48 3389.52 3670.09 3397.03 269.39 7.9 
AUC0-∞  
(ng*hr/mL) 3203.97 3416.66 3688.64 3436.43 242.94 7.1 
Vss  
(L/kg) 0.6348 0.8337 1.001 0.8231 0.1833 22.3 
Cl 
(mL/min/kg) 26.01 24.39 22.59 24.33 1.710 7.0 
MRT 
(hr) 0.4067 0.5697 0.7385 0.5716 0.1659 29.0 
T1/2 




Table C.2 Pharmacokinetic parameters for 20 mg/kg HCI2509 dosed as solution PO. 
Parameter  
Time (hr) Cp HCI2509 (ng/ml) 
 
 
Mice 1-7 Mice 8-14 Mice 15-21 Mean STDEV %CV 
0.25 638 1162 852 884 263 29.8 
0.5 851 1163 792 935 199 21.3 
1 346 440 999 595 353 59.3 
2 246 219 231 232 13.5 5.8 
4 69 302 155 175 117 67.2 
8 56 422 64 181 209 115.7 
24 3 3 10 5.33 4.04 75.8 
       Cmax 
(ng/mL) 851 1163 999 1004.33 156.07 15.5 
Tmax 
(hr) 0.5 0.5 1 0.6667 0.28868 43.3 
AUC0-t  
(ng*hr/mL) 1898.13 6535.13 2790.75 3741.33 2460.32 65.8 
AUC0-∞  
(ng*hr/mL) 1916.39 6546.98 2862.96 3775.44 2446.44 64.8 
AUMC0-∞  
 
(ng*hr^2/mL) 7630.51 39569.1 12798.41 19999.3 17143.75 85.7 
MRT 
(hr) 3.982 6.044 4.470 4.832 1.078 22.3 
T1/2 
(hr) 4.220 2.739 5.005 3.988 1.151 28.8 




Table C.3 Pharmacokinetic parameters for 50 mg/kg HCI2509 dosed as suspension PO. 
Parameter  
Time (hr) Cp HCI2509 (ng/ml) 
 
 
Mice 1-8 Mice 9-16 Mice 17-24 Mean STDEV %CV 
0.25 129 99 69 99 30 30.3 
0.5 151 56 82 96.33 49.10 51.0 
1 79 154 66 99.67 47.50 47.7 
2 122 192 94 136 50.48 37.1 
4 251 202 126 193 62.98 32.6 
8 90 52 207 116.33 80.79 69.4 
12 25 27 40 30.67 8.14 26.6 
24 10 13 11 11.33 1.53 13.5 
       Cmax 
(ng/mL) 251 202 207 220 26.96 12.3 
Tmax 
(hr) 4 4 8 5.33 2.309 43.3 
AUC0-t  
(ng*hr/mL) 1704.13 1557.25 1830.5 1697.29 136.75 8.1 
AUC0-∞  
(ng*hr/mL) 1768.92 1718.33 1896.80 1794.7 91.98 5.1 
AUMC0-∞  
(ng*hr^2/mL) 12168.5 15122.1 15901.8 14397.5 1969.4 13.7 
MRT 
(hr) 6.879 8.800 8.384 8.0210 1.010 12.6 
T1/2 
(hr) 4.491 8.589 4.172 5.752 2.461 42.8 














Figure C.1 Typical standard curves to quantitate HCI2509 by LC-MS/MS. Known 
concentrations of HCI2509 are extracted from mouse plasma, plotted as a standard curve 
and used to determine the concentrations of HCI2509 in mouse plasma. The limit of 
detection was determine using LOD=3.3*(SD/S), where SD is the standard deviation in 
the y-intercept and S is the slope.  LOD was determined to be 43 ng/mL. Linearity was 





Figure C.2 Plasma concentration-time curves for HCI2509 in mice as determined by LC-
MS/MS. The data in Tables C1-C3 plotted on a linear scale. Data are visualized as mean 
and standard deviation (n=3). 
 
 
Figure C.3 Plasma concentration-time curves for HCI2509 in mice as determined by LC-
MS/MS – semilog. The data in Tables C1-C3 plotted on a linear scale. Data are visualized 





Figure C.4 Plasma concentration-time curves for 40 mg/kg HCI2509 in mice as 
determined by LC-MS/MS. Linear plot of 50/50 PEG400/PBS formulation used for 
efficacy studies. Data are visualized as mean and standard deviation (n=3). 
 
 
Figure C.5 Plasma concentration-time curves for 40 mg/kg HCI2509 in mice as 
determined by LC-MS/MS – semilog. Semilog plot of 50/50 PEG400/PBS formulation 
used for efficacy studies. Data are visualized as mean and standard deviation (n=3). 
